Use and Evaluation of Statistical Methods for Personalized Medicine in Oncology by Li, Pin
Use and Evaluation of Statistical Methods for
Personalized Medicine in Oncology
by
Pin Li
A dissertation submitted in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
(Biostatistics)
in The University of Michigan
2020
Doctoral Committee:
Associate Professor Matthew J. Schipper, Co-Chair
Professor Jeremy M.G. Taylor, Co-Chair
Associate Professor Phil S. Boonstra
Professor Theodore S. Lawrence
Pin Li
pinli@umich.edu
ORCID iD: 0000-0003-4508-3762
c© Pin Li 2020
All Rights Reserved
ACKNOWLEDGEMENTS
I would like to express my deepest gratitude to my co-advisor, Prof. Jeremy
Taylor for his guidance and advice. His vision, diligence, motivation and patience
have deeply inspired me. It was a great privilege and honor to work and study under
his guidance.
I would like to express my heartiest gratitude to my co-advisor, Prof. Matthew
Schipper for his guidance and support. He has provided me with invaluable research
opportunities that help me build confidence as a researcher. I would also like to thank
him for his encouragement, reliability and great sense of humor.
Many thanks to my dissertation committee member, Prof. Phil Boonstra and
Prof. Theodore S. Lawrence for their helpful suggestions in the methodology and
application in my dissertation research.
I would like to thank my supervisors and collaborators in my GSRA projects,
including Prof. Jill Becker from Department of Psychology, Prof. Ananda Sen and
Prof. Wen Ye from Department of Biostatistics, Prof. Michelle Mierzwa, Prof. Yue
Cao, Prof. Michelle Kim, Prof. Daniel Spratt and Dr. Laila Gharzai from Department
of Radiation Oncology.
I would like to thank all the faculty members and staffs in the Biostatistics De-
partment for establishing a nurturing environment for future scientists. My sincere
thanks also go to Prof. Veera Baladandayuthapani and the TaBaBoo research group
for their many helpful comments and support. I would also like to thank my fellows
and friends in the Biostatistics Department.
ii
Last but not least, I am extremely grateful to my parents for their love, caring and
sacrifices for educating and preparing me for my future. I want to thank my husband
Dr. Wei Zhao, who has always been a great and patient listener to my struggles and
a firm supporter of the decisions I’ve made. They all kept me going and I could not
make this far without their trust and support.
iii
TABLE OF CONTENTS
ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . ii
LIST OF TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . vi
LIST OF FIGURES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . viii
LIST OF APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . xi
ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . xii
CHAPTER
I. Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
II. Evaluation of Predictive Model Performance of an Existing
Model in the Presence of Missing Data . . . . . . . . . . . . . 6
2.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 6
2.2 Methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2.2.1 Complete case analysis . . . . . . . . . . . . . . . . 12
2.2.2 Multiple Imputation . . . . . . . . . . . . . . . . . . 13
2.2.3 Inverse Probability Weighting . . . . . . . . . . . . 14
2.2.4 Augmented Inverse Probability Weighting . . . . . . 15
2.2.5 Consistency of IPW and AIPW estimators . . . . . 17
2.3 Simulation Studies . . . . . . . . . . . . . . . . . . . . . . . . 18
2.3.1 Simulation results . . . . . . . . . . . . . . . . . . . 21
2.4 Application . . . . . . . . . . . . . . . . . . . . . . . . . . . . 26
2.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
III. A Utility Approach to Individualized Optimal Dose Selection
Using Biomarkers . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
iv
3.2 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
3.2.1 Binary Outcome Setting . . . . . . . . . . . . . . . 36
3.2.2 Multiple Outcome Setting . . . . . . . . . . . . . . 39
3.3 Simulation Studies . . . . . . . . . . . . . . . . . . . . . . . . 41
3.4 Application . . . . . . . . . . . . . . . . . . . . . . . . . . . . 49
3.5 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 52
IV. Utility Based Approach in Individualized Optimal Dose Se-
lection Using Machine Learning Methods . . . . . . . . . . . . 55
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . 55
4.2 Utility function and matrix . . . . . . . . . . . . . . . . . . . 58
4.3 Model building . . . . . . . . . . . . . . . . . . . . . . . . . . 60
4.3.1 Random forest . . . . . . . . . . . . . . . . . . . . . 60
4.3.2 Gaussian process . . . . . . . . . . . . . . . . . . . 61
4.4 Optimal dose finding . . . . . . . . . . . . . . . . . . . . . . . 63
4.4.1 Modified utility functions . . . . . . . . . . . . . . . 64
4.4.2 Use uncertainty of the estimation . . . . . . . . . . 66
4.5 Simulation studies . . . . . . . . . . . . . . . . . . . . . . . . 67
4.5.1 Settings and scenarios . . . . . . . . . . . . . . . . . 67
4.5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . 72
4.5.3 Parametric vs non-parametric models . . . . . . . . 79
4.6 Application . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.7 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
V. Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
A.1 Differences between optimizing the likelihood, the AUC and
the Brier Score . . . . . . . . . . . . . . . . . . . . . . . . . . 94
A.2 Consistency of IPW and AIPW estimators for Brier score . . 96
A.3 Additional simulation results for correlated covariates . . . . 97
A.4 Implementing AIPW and IPW estimators when more than one
variable has missing values . . . . . . . . . . . . . . . . . . . 97
A.5 Simulation results when more than one variable has missing
values . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 100
B.1 The minimizer to problem (3.4) always satisfies β+j β
−
j = 0 for
j = 1, ..., 2p+ 1 . . . . . . . . . . . . . . . . . . . . . . . . . . 104
B.2 Additional simulation results . . . . . . . . . . . . . . . . . . 106
C.1 Using copulas to link two marginal distributions . . . . . . . 108
C.2 Additional results . . . . . . . . . . . . . . . . . . . . . . . . 109
BIBLIOGRAPHY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
v
LIST OF TABLES
Table
2.1 List of methods for comparison. * indicates methods for which the
weight model is misspecified under MAR(X,Y). † indicates methods
for which the imputation model is misspecified. . . . . . . . . . . . 20
2.2 CAPRA score . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3 CAPRA score distribution and predicted probabilities derived from
the CAPRA score. . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3.1 Simulation results. Summary of average Efficacy improvement com-
pared with fixed dose with P(Toxicity) constrained to be ≤ 0.2. Re-
sults from 1000 simulated trials. Each scenario true logistic mod-
els for E and T include main effect for the biomarkers, dose and
biomarker-dose interactions, with coefficients as shown below. . . . . 46
3.2 Descriptive statistics of patients (n=105) . . . . . . . . . . . . . . . 50
3.3 Variable selections in each model . . . . . . . . . . . . . . . . . . . 51
4.1 Utility matrix . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.2 Table of probabilities . . . . . . . . . . . . . . . . . . . . . . . . . . 59
4.3 utility matrix with two parameters . . . . . . . . . . . . . . . . . . 59
4.4 List of scenarios . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
4.5 List of methods. RF denotes random forest, GP denotes Gaussian
process . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
4.6 Comparison of all methods under scenario 1 with utility 1,2,3 . . . . 74
4.7 Comparison of percentage of utility function improvement under all
scenarios with utility 1 . . . . . . . . . . . . . . . . . . . . . . . . . 78
4.8 Comparison of percentage of utility function improvement under se-
lected scenarios with utility 1 for selected non-parametric and para-
metric methods . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
4.9 Descriptive statistics of patients (n=109) . . . . . . . . . . . . . . . 82
B1 Simulation results for two toxicities. Summary of average Efficacy
improvement compared with fixed dose with P(Toxicity1) constrained
to be ≤ 0.2 and P(Toxicity2) constrained to be ≤ 0.23. Results from
1000 simulated trials. Each scenario true logistic models for E, T1
and T2 include main effect for the biomarkers, dose and biomarker-
dose interactions, with coefficients as shown below. . . . . . . . . . . 106
vi
C1 List of scenarios to compare parametric vs non-parametric models . 112
vii
LIST OF FIGURES
Figure
2.1 Simulation results of mean and relative SD of AUC for existing model
M1: correct model. Column A denotes mean AUC. Column B de-
notes SD relative to full data analysis. The four rows are different
missingness mechanisms. . . . . . . . . . . . . . . . . . . . . . . . 21
2.2 Simulation results of mean and relative SD of Brier score for existing
model M1: correct model. Column A denotes mean BS. Column B
denotes SD relative to full data analysis. The four rows are different
missingness mechanisms. . . . . . . . . . . . . . . . . . . . . . . . 22
2.3 Simulation results of mean and relative SD of AUC for existing model
M2: best model based on just X1, X2. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows
are different missingness mechanisms. . . . . . . . . . . . . . . . . 23
2.4 Simulation results of mean and relative SD of BS for existing model
M2: best model based on just X1, X2. Column A denotes mean BS.
Column B denotes SD relative to full data analysis. The four rows
are different missingness mechanisms. . . . . . . . . . . . . . . . . 24
2.5 Simulation results of mean and relative SD of AUC for existing model
M3: poor model based on X1, X2, X3. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows
are different missingness mechanisms. . . . . . . . . . . . . . . . . 25
2.6 Simulation results of mean and relative SD of BS for existing model
M3: poor model based on X1, X2, X3. Column A denotes mean BS.
Column B denotes SD relative to full data analysis. The four rows
are different missingness mechanisms. . . . . . . . . . . . . . . . . 26
viii
2.7 Simulation results of mean and relative SD of BS for existing model
M4: different intercept model. Column A denotes mean BS. Column
B denotes SD relative to full data analysis. The four rows are different
missingness mechanisms. . . . . . . . . . . . . . . . . . . . . . . . 27
2.8 Varying estimates of mean and 95% confidence interval of AUC and
Brier Scores for prostate cancer example, based on how missing data
are handled . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
3.1 Top: Individual level E-T plot with choice of dose with theoretical
βE, βT for three subjects. The utility curve uses θ = 1. Bottom:
Individual level optimal dose as a function of θ for the same three
subjects. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
3.2 Left: Population level E-T plot with choice of θ with theoretical
βE, βT , Right: Population level E-T trade-off at different toxicity
tolerance levels. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 43
3.3 Simulation results for scenario 0. Boxplot of average efficacy with
same toxicity for 1000 simulation trials. The compared methods
are theory with true coefficients; FS: Forward Selection; LASSO;
cLASSO: constrained LASSO; FD: Fixed Dosing. All methods are
constrainted at P(T)=0.20. Means are 0.599, 0.528, 0.528, 0.539,
0.452, respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
3.4 Simulation results for the null scenario. Boxplot of average efficacy
with same toxicity for 1000 simulation trials. The compared meth-
ods are theory with true coefficients; FS: Forward Selection; LASSO;
cLASSO: constrained LASSO; FD: Fixed Dosing. All methods are
constrainted at P(T)=0.20. Means are 0.503, 0.470, 0.490, 0.491,
0.499,, respectively. . . . . . . . . . . . . . . . . . . . . . . . . . . . 45
3.5 Comparison of selected optimal dose and actual dose received for all
the patients. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 53
4.1 Comparison of utility function contours. (a) U¯ with ω1 = ω2 = 0.5,
(b) U¯1 with ω1 = ω2 = 0.5, (c) U¯2 with ω1 = ω2 = 0.5, δ = 0.1, (d)
U¯3 with ω1 = ω2 = 0.5, δ = 0.1, (e) U¯ with ω1 = 0.3, ω2 = 0.5 and
independent E and T, (f) U¯ with ω1 = 0.5, ω2 = 0.3 and independent
E and T, (g) U¯ with ω1 = 0.5, ω2 = 0.3 and cor(E,T)=0.8, (h) U¯ with
ω1 = 0.5, ω2 = 0.3 and cor(E,T)=-0.8. . . . . . . . . . . . . . . . . . 65
4.2 Distribution of optimal dose of n=200 patients for different methods
under scenario 1 with utility 1 . . . . . . . . . . . . . . . . . . . . . 73
ix
4.3 Simulation results for scenario 0, 1, 2, 3 under utility 1. Boxplot of
population average of expectation of Utility for 1,000 simulation trials. 76
4.4 Boxplot of optimal doses by different methods for the 109 patients . 83
4.5 Optimal dose selected by different methods for three patients. Dose-
efficacy and dose-toxicity curves are denoted by solid lines, expec-
tation of utility values by different methods are denoted by dashed
lines, optimal dose selected by different methods are denoted by points. 85
A1 Simulation results of mean and relative SD of AUC for existing model
M1: cor(X1, X3) = −0.5. Column A denotes mean AUC. Column B
denotes SD relative to full data analysis. The four rows are different
missingness mechanisms. . . . . . . . . . . . . . . . . . . . . . . . 98
A2 Simulation results of mean and relative SD of BS for existing model
M1: cor(X1, X3) = −0.5. Column A denotes mean BS. Column B
denotes SD relative to full data analysis. The four rows are different
missingness mechanisms. . . . . . . . . . . . . . . . . . . . . . . . 99
A3 Simulation results of mean and relative SD of AUC for existing model
with block missing of more covariates. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows
are different missingness mechanisms. . . . . . . . . . . . . . . . . 100
A4 Simulation results of mean and relative SD of AUC for existing model
with scatter missing of more covariates. Column A denotes mean
AUC. Column B denotes SD relative to full data analysis. The four
rows are different missingness mechanisms. . . . . . . . . . . . . . 101
A5 Simulation results of mean and relative SD of AUC for existing model
with monotone missing of more covariates. Column A denotes mean
AUC. Column B denotes SD relative to full data analysis. The four
rows are different missingness mechanisms. . . . . . . . . . . . . . 102
C1 Simulation results for scenario 4-7 under utility 1. Boxplot of popu-
lation average of expectation of Utility for 1,000 simulation trials. . 110
C2 Simulation results for scenario 8-10 under utility 1. Boxplot of pop-
ulation average of expectation of Utility for 1,000 simulation trials. . 111
C3 Optimal dose selected by different methods for three patients. Dose-
efficacy and dose-toxicity curves are denoted by solid lines, expec-
tation of utility values by different methods are denoted by dashed
lines, optimal dose selected by different methods are denoted by points.113
x
LIST OF APPENDICES
Appendix
A. Appendices for Chapter II . . . . . . . . . . . . . . . . . . . . . . . . 94
B. Appendices for Chapter III . . . . . . . . . . . . . . . . . . . . . . . . 104
C. Appendices for Chapter IV . . . . . . . . . . . . . . . . . . . . . . . . 108
xi
ABSTRACT
The goal of personalized medicine is to give the right treatment to the right pa-
tient at the right dose using all we know about the patient. With the increasing
availability of biomarkers and prediction models, there is the potential for individual-
ized treatment based on patient specific factors. There are many statistical challenges
associated with achieving this goal. One is how to develop and assess good predictions
models. Another is how to define a criteria for an optimal treatment when there are
multiple outcomes and then how to analyze available data to determine the optimal
treatment for each future patient.
In Chapter II, we consider the assessment of prediction models using data with
missing biomarker values. We propose inverse probability weighted (IPW) and aug-
mented inverse probability weighted (AIPW) estimates of the area under the ROC
curve (AUC) and Brier Score to handle the missing data. AIPW is a double-robust
method that is robust to the misspecification of either a model for the missingness
mechanism or a model for the distribution of the missing variable. We evaluated
the performance of IPW and AIPW in comparison with multiple imputation (MI) in
simulation studies under missing completely at random (MCAR), missing at random
(MAR), and missing not at random (MNAR) scenarios. We illustrate these methods
using an example from prostate cancer.
In Chapters III and IV we consider the setting where there is an existing dataset of
patients treated with heterogeneous doses and including binary efficacy and toxicity
outcomes and patient factors such as clinical features and biomarkers. The goal is to
xii
analyze the data to estimate an optimal dose for each (future) patient based on their
clinical features and biomarkers.
In Chapter III, we propose an optimal individualized dose finding rule by maxi-
mizing utility functions for individual patients while limiting the rate of toxicity. The
utility is defined as a weighted combination of efficacy and toxicity probabilities. We
model the binary efficacy and toxicity outcomes using logistic regression with dose,
biomarkers and dose-biomarker interactions. To incorporate the large number of po-
tential parameters, we use the LASSO method. We additionally constrain the dose
effect to be non-negative for both efficacy and toxicity for all patients. The proposed
methods are illustrated using a dataset of patients with lung cancer treated with
radiation therapy.
In Chapter IV, we extend the approach of Chapter III and propose to use flexible
machine learning methods such as random forests and Gaussian processes to build
models for efficacy and toxicity depending on the dose and biomarkers. In addition,
we allow for dependence between efficacy and toxicity. A copula is used to model
the joint distribution of the two outcomes and the estimates are constrained to have
non-decreasing dose-efficacy and dose-toxicity relationships. Numerical utilities are
assigned to each potential outcome pair, which allow the improvement in the utility
due to a change in efficacy to depend on the level of toxicity. For each patient,
the optimal dose is chosen to maximize the utility function or the posterior mean of
the utility function. We further adjust the utility function with more constraints to
incorporate clinical requirements, and consider the uncertainty in the estimation of
the utility function in the optimal dose selection. The various models and methods
are evaluated in a simulation study and illustrated using data from a lung cancer
study.
xiii
CHAPTER I
Introduction
Traditionally, standards of care have been built based on knowledge from clin-
ical studies and evidence-based medicine and given in medical practice. With the
progress in basic science, scientists are developing and using diagnostic tests based
on genetics or other molecular mechanisms to better predict patients’ responses to
targeted therapy. The use of biomarkers provides the potential to drive therapeutic
decision making and tailor medical care. Personalized medicine has been focusing on
optimizing the assignment of therapy by treating patients with the right drug at the
right dose at the right time.
The personalized medicine approach can replace the traditional “one size fits all”
medicine and move from a reactive to a proactive discipline that is predictive, person-
alized, preventive and participatory [17]. However, the field of personalized medicine
raises many challenges that need to be overcome, such as integration of diverse data
from the various hierarchical levels of biological information, difficulties identifying
and validating molecular markers, and ultimately create effective predictive and ac-
tionable models. Besides technical challenges, there are also societal challenges in-
cluding education and communication with patients, physicians, and the health-care
community about the power of personalized medicine to accelerate the application of
it.
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The statistical challenges associated with personalized medicine are to provide
effective tools for construction and evaluation of evidence-based personalized inter-
vention strategies. Multiple regression has been widely used for model building to
identify predictive biomarkers with data from randomized clinical trials (RCT). In
the absence of randomization, the propensity score can be used to reweight the ob-
servational data to attenuate selection bias. With a large set of biomarkers, variable
selection methods are needed to detect predictive biomarkers from high-dimensional
sources. More advanced methods are proposed to improve the robustness against
misspecification of regression models, and well established classification methods and
other popular machine learning techniques can alternatively be customized to avoid
pre-specification of parametric models [30].
Because models are estimated conditionally given the observed data, they neglect
to quantify the extent of uncertainty for future patients. Thus external validation and
internal validation are needed, and cross-validation (CV) and bootstrap resampling
techniques are commonly used for the later. To assess the model performance, the
Brier score (BS) and receiver operating characteristic (ROC) curves are two common
metrics used to evaluate existing prediction models of a binary outcome. The assess-
ment of prediction models using data with missing covariate values is challenging.
There are general methods for handling missing data of multiple imputation (MI)
and inverse probability weighting [27, 41]. These methods make use of specific statis-
tical models, which have to be selected. How to select these models is an important
question. When using MI to develop a prediction model, Moons et. al. [33] showed
that it is important to include the outcome variable within the selected imputation
models. How to construct the statistical models in either MI or IPW methods to give
valid results when assessing an exisiting prediction model is not known.
In Chapter II, we propose inverse probability weighted (IPW) and augmented
inverse probability weighted (AIPW) estimates of the area under the ROC curve
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(AUC) and BS to handle the missing data. AIPW is a double-robust method that is
robust to the misspecification of either a model for the missingness mechanism or a
model for the distribution of the missing variable [1]. An alternative approach uses
multiple imputation (MI), which requires a model for the distribution of the missing
variable. We evaluated the performance of IPW and AIPW in comparison with MI in
simulation studies under missing complete at random (MCAR), missing at random
(MAR), and missing not at random (MNAR) scenarios. When there are missing
observations in the data, MI and IPW can be used to obtain unbiased estimates of
BS and AUC if the imputation model for the missing variable or the model for the
missingness is correctly specified. MI is more efficient than IPW. AIPW can improve
the efficiency of IPW, and also achieves double robustness from misspecification of
either the missingness model or the imputation model. The outcome variable should
be included in the model for the missing variable under all scenarios, while it only
needs to be included in missingness model if the missingness depends on the outcome.
We illustrate these methods using an example from prostate cancer.
In early phase clinical trials of oncology, efficacy such as disease progression and
toxicity such as side effects are used to evaluate the performance of a treatment. Dif-
ferent approaches can be used to measure the trade-off between potentially beneficial
and potentially harmful outcomes for a patient, such as utility function [40], utility
matrix [19] or utility contours [46]. There has been much work on how to choose
the individualized optimal treatment when there is a choice between two treatments
and there is a single outcome measure [12, 54, 53, 55]. There has been much less
research on methods to find individualized treatment rule in the setting with more
than two treatments and more than one outcome. We consider the setting where
there is an existing dataset of patients treated with heterogeneous doses and includ-
ing binary efficacy and toxicity outcomes and patient factors such as clinical features
and biomarkers. The goal is to analyze the data to estimate an optimal dose for each
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(future) patient based on their clinical features and biomarkers. With the increasing
availability of validated biomarkers, there is the need to identify the patient specific
factors that is related to the individualized dosing rule. In many settings, including
oncology, increasing the dose of treatment usually results in both increased efficacy
and toxicity, and how to incorporate this is challenging. The efficacy and toxicity out-
comes could be correlated or independent given the dose, and both of them should
be used to decide the optimal dose.
In Chapter III, we propose an optimal individualized dose finding rule by maxi-
mizing utility functions for individual patients while limiting the rate of toxicity [49].
The utility is defined as a weighted combination of efficacy and toxicity probabili-
ties. This approach maximizes overall efficacy at a prespecified constraint on overall
toxicity. We model the binary efficacy and toxicity outcomes using logistic regres-
sion with dose, biomarkers and dose-biomarker interactions. To incorporate the large
number of potential biomarkers, we use the LASSO method [47]. We additionally
constrain the dose effect to be non-negative for both efficacy and toxicity for all pa-
tients. Simulation studies show that the utility approach combined with any of the
modeling methods can improve efficacy without increasing toxicity relative to fixed
dosing. The proposed methods are illustrated using a dataset of patients with lung
cancer treated with radiation therapy.
In Chapter IV, we extend the approaches in Chapter III by relaxing the assumption
of independence of efficacy and toxicity in modeling. We propose to use flexible
machine learning methods such as random forest [24] and Gaussian process [51] to
build models for efficacy and toxicity depending on the dose and biomarkers. Copula
[43] is used to model the joint distribution of the two outcomes and the estimates
are constrained to have non-decreasing dose-efficacy and dose-toxicity relationships.
Numerical utilities are assigned to each potential outcome pair, and these allow the
improvement in the utility due to a change in efficacy to depend on the level of toxicity.
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For each patient, the optimal dose is chosen to maximize the utility function or the
posterior mean of the utility function. We further adjust the utility function with
more constraints to incorporate clinical requirements, and consider the uncertainty in
the estimation of the utility function in optimal dose selection. The various models
and methods are evaluated in a simulation study, where we find that using Gaussian
processes to model the probability of efficacy and toxicity and using the posterior
mean of the utility function has good properties. We also compare the proposed
random forest and Gaussian process methods with the parametric models in Chapter
III to illustrate their pros and cons.
To conclude, the goal is to construct and evaluate models, which can accurately
predict either the clinical outcome or the treatment effect for individual patients, and
then optimize the outcome or treatment effect for new patients. This dissertation
makes a contribution towards the model estimation and evaluation in oncology and
proposes novel methodologies in optimal individualized dose finding.
5
CHAPTER II
Evaluation of Predictive Model Performance of an
Existing Model in the Presence of Missing Data
2.1 Introduction
In clinical research, patient information such as clinical features, diagnostic tests
and biomarkers are often used to help with diagnosis or to provide prognosis of a
future outcome for a patient with disease. When the outcome of interest is binary, a
typical prediction model will numerically combine the covariates, for example using a
linear combination, to estimate the predicted probability of the binary outcome. The
evaluation of an existing prediction model in a different populations is of consider-
able interest. If a model is to be transportable to other populations, it needs to be
validated, which is usually thought of as meaning that it has similar and good perfor-
mance in other populations. The performance of existing prediction models can be
assessed using a variety of metrics, such as the Brier score to indicate accuracy of the
probabilistic predictions, and area under the receiver operating characteristic (ROC)
curve (or the concordance statistic) for discriminative ability [44]. Very often, covari-
ate values will be missing for some patients. The assessment of prediction models in
data with missing covariate values is a challenge. The context we are considering is
that the existing model or models were developed on other datasets, which we call
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the external data, and are already completely specified. We do not have access to the
data used to develop these models. Rather, our goal is to assess the performance of
the existing model in an available dataset, which we call the internal data, that has
missing values for some covariates and we want to get valid and efficient estimates of
the BS and the AUC.
In general there are two types of methods for estimation in the presence of missing
data, one is based on multiple imputation (MI) and the other is based on inverse prob-
ability weighting (IPW). For MI, a model for the distribution of the missing variable,
or variables, needs to be specified. For IPW method, a model for the probability of
missingness needs to be specified, which is also called the weight model. For multiple
imputation, M completed datasets are created and M model performance measures
can be estimated from each of the completed dataset and then averaged [27]. Al-
ternatively, an overall measure of model performance can be estimated directly from
a simple completed dataset that includes the average of the M predictions for each
missing value. As previously recommended [52], the former is preferred. The analysis
of only the observations with complete data is frequently biased, and inverse proba-
bility weighting is a commonly used approach to correct their bias [41]. It is also used
to adjust for unequal sampling fractions in sample surveys and causal inference [31].
Augmented inverse probability weighting (AIPW) has been proposed as an extension
of IPW. It is a double-robust method that is robust to the misspecification of either a
model for the missingness mechanism or a model for the distribution of the variables
with missing values (but not both) [1]. AIPW generally results in improved efficiency
compared to IPW, although this is not guaranteed to be the case..
When analyzing data with missing values an important consideration is the miss-
ingness mechanism, and the mechanism will impact the properties and merits of
different methods. Missing complete at random (MCAR) is when the probability of
any variable being missing for a subject does not depend on the value of any of the the
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variables. Generally all methods will work under MCAR. Analysis of the complete
cases will be unbiased, but are frequently quite inefficient compared to other meth-
ods, depending on the amount of missingness. Missing at random (MAR) is when the
probability of being missing can depend on other covariates, but only those that are
observed. In general MI, IPW and AIPW are vaild under MAR, if models are appro-
priately specified. Complete case analysis is frequently biased under MAR. Missing
Not at Random (MNAR) is when the probability of missing depends on the value of
variables that are fully observed, including the unobserved value of the variable itself.
Generally all methods are biased under MNAR.
A basic question for all the above MI, IPW and AIPW methods is whether the
observed data for the outcome variable should be included in the required imputation
models or weight models. This is also related to how the covariate is missing, whether
the missingness is completely at random, or depend on other covariates and/or the
outcome, or the covariate itself. The argument in favor of including the outcome
variable in these models is from the theoretical developments associated with missing
data and multiple imputation. In general, it is well known that for inference about
a quantity of interest it is necessary to include the outcome variable as one of the
variables in the imputation model when developing a new prediction model. Omitting
the outcome variable can lead to biased estimates [33]. In general notation, if Q is the
quantity of interest, and D = (Dobs, Dmis) is the data where Dobs and Dmis denote the
observed and missing data, then from a Bayesian perspective, inference about Q is
based on its posterior distribution P (Q|Dobs). This posterior distribution can be writ-
ten as P (Q|Dobs) =
∫
P (Q|Dobs, Dmis)P (Dmis|Dobs)pDmis, and this applies whether
Q is a simple parameter in a model or a more complex function i.e. such as the Brier
Score or the AUC. This formula is the recipe for multiple imputation and motivates
imputation of the missing data using P (Dmis|Dobs), followed by inference for Q using
the complete data (Dobs, Dmis), and repeating these steps many times and averaging
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them. Since in our setting the outcome variable is part of Dobs, it is clear that the
outcome variable should be used as part of the imputation scheme. In practice, the
general recommendation for MI is that the imputation model should include every
variable that predicts the incomplete variable, and sometimes the imputation model
can contain more variables than will be used in the final analysis [50].
The intuitive argument against including the outcome variable in the models used
for imputation is the belief that there is some circularity. Since we are trying to
evaluate how good a model is at predicting outcome, the thinking is that we don’t
want to use the outcome to help impute the missing covariates, because then we will
make the model look better than it really is. However, Moons et al argued that
imputation of missing values using all other information will not create information.
It only makes use of the strength of associations between predictors and outcomes
present in the complete cases, to enable valid analyses [33]. The additional intuitive
argument against using the outcome variable is that the intended use of these models
is in the situation where we want to make a prediction for a single patient and we only
have covariates available and the outcome is not known. It is certainly a challenge of
how to make a prediction if some of the covariates are missing, but this is a different
situation than ours of evaluating a existing prediction model using a new dataset.
In this paper, we propose IPW and AIPW estimates of AUC and Brier score
to handle the missing data and evaluate their prediction performance in comparison
with MI by simulation. We focus on including the outcome or not in the weight
models or imputation models. The missing mechanisms could be MCAR, MAR and
MNAR. We consider a variety of existing prediction models including ones that are
both consistent with and not consistent with the internal data distribution, and ones
that depend on a subset of the covariates. An example from prostate cancer is used
as an illustration of the proposed methods.
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2.2 Methods
We consider the setting in which we have available an internal dataset of size N ,
consisting of binary outcome Y and p-dimensional vector of covariates X. Let Ri = 1
if there are no missing X values for subject i, else Ri = 0 if there are missing values.
Assume there is an existing external model, that requires as input the variables X or
a subset of the variables, and produces as output an estimate of the probability that
Y = 1, denoted by pˆ(Y = 1|X). We use notation I to denote distributions associated
with the available or internal data, and E to denote the distributions associated with
the external data that was used to build the existing model. Let FI(X) and FI(Y |X)
denote the true probability distribution functions for the internal data. Thus FI(X)
is the density of X if X is continuous and FI(Y = y|X = x) = PI(Y = y|X = x). Let
FE(X) and FE(Y |X) denote the true distributions for the external data. We would
expect some of the X’s to be correlated with each other.
The existing model pˆ(Y = 1|X) is an approximation to FE(Y = 1|X), and it
is usually a monotonic function of a weighted combination of covariates, denoted as
g(βX). The estimates of β could be good estimates if for example the external dataset
is large and good methods were used, or they could be poor estimates if the external
dataset is small or poor methods were used. From the internal dataset with sample
size N that are sampled from FI(X) and FI(Y |X), we can calculate the Brier score
and AUC. The BS is given by
BS =
1
N
N∑
i=1
(Yi − pˆi)2 (2.1)
where pˆi =P(Y = 1|Xi) is obtained from the existing model.
The Area Under the Curve (AUC), which is equivalent to the Concordance-index
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(C-index) for a binary outcome, is estimated using
AUC/C − index =
N∑
i=1
N∑
j=1
I(βXi > βXj)I(Yi > Yj)
N∑
i=1
N∑
j=1
I(Yi > Yj)
(2.2)
An alternative way to estimate the AUC is to first estimate the ROC curve and
then calculate the area under it. Let n1 denote the number of cases, n0 denote the
number of controls, and n1 + n0 = N . Let X1 denote the covariates in cases and X0
denote the covariates in controls. The ROC curve depicts relative trade-offs between
true positive rate (TPR) and false positive rate(FPR),
TPR(c) = Pr(βX1 ≥ c) = 1
n1
n1∑
i=1
I(βXi ≥ c)
FPR(c) = Pr(βX0 ≥ c) = 1
n0
N∑
j=n1+1
I(βXj ≥ c)
ROC(c) = TPR(FPR−1(c))
AUC =
1∫
0
ROC(c)dc
(2.3)
The integration of ROC to calculate the AUC is performed numerically. The
quantities called BS and AUC given above are estimates of population quantities,
which we call TrueBrierI(pˆ) and TrueAUCI(pˆ). Given the distribution FI(X) and
FI(Y |X), for any existing formula pˆ that provides a probability that Y=1 given X,
the true Brier Score (BS) is defined as
TrueBrierI(pˆ) =
1∑
Y=0
∫
X
(Y − pˆ)2FI(Y |X)FI(X)dX (2.4)
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For covariates in cases X1 and controls X0, denote their distributions as FI(X1) =
FI(X|Y = 1) and FI(X0) = FI(X|Y = 0), respectively. Then the true AUC is
TrueAUCI(pˆ) = Pr(βX1 > βX0) =
∫
X1
∫
X0
I(βX1 > βX0)FI(X1)FI(X0)dX1dX0
(2.5)
Equation 2.4 and 2.5 give the true values of BS and AUC for a fixed β. The goal is
to get good estimates of these population quantities TrueAUCI(pˆ) and TrueBrierI(pˆ),
using the available data in the internal dataset of size N . A good estimate is one that
has small bias, low variability and is robust to model misspecification.
Also note from equation 2.4 that the true value depends on both FI(Y |X) and
FI(X), and similarly for equation 2.5. This makes it clear that even if the existing
prediction model for Y given X is correct for the internal distribution, it will not
usually lead to the same AUC and BS because these depend on the X distribution
as well. In practice it would seem likely that the internal and external distributions
of the X’s do differ.
In real data analysis with large sample size, missing data are a common occurrence.
Suppose our dataset has missing values for some covariates of X, and the missingness
may be MCAR, MAR or MNAR. The practical question we are trying to address
is how to get a good estimate of TrueAUCI(pˆ) and TrueBrierI(pˆ) from the available
dataset with missing covariates. The best conceivable estimates are the ones that
would have been obtained using equations 2.1,2.2 and 2.3 if there had been no missing
data.
2.2.1 Complete case analysis
Using only complete case (i.e Ri = 1) the simplest estimates are
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BSCC =
N∑
i=1
(Yi − pˆi)2Ri∑N
i=1Ri
(2.6)
C − indexCC =
N∑
i=1
N∑
j=1
I(βXi > βXj)I(Yi > Yj)RiRj
N∑
i=1
N∑
j=1
I(Yi > Yj)RiRj
(2.7)
For AUC,
TPRCC(c) =
n1∑
i=1
I(βXi ≥ c)Ri
n1∑
i=1
Ri
FPRCC(c) =
n0∑
j=1
I(βXj ≥ c)Rj
n0∑
j=1
Rj
(2.8)
However, these estimates may be biased in MAR and MNAR settings and may lack
efficiency in MCAR situations.
2.2.2 Multiple Imputation
When there is partially missing in X, we can do Multiple Imputation (MI) to
impute the missing values based on the available data, then average the predicted
BS and AUC from the multiple imputed datasets using Rubin’s rule. The first step
is to impute the missing values by drawing a value of Xmis from a model either
for F (Xmis|Xobs, Y ) or for F (Xmis|Xobs), and then apply the external model on the
imputed complete data to get the predictions of Y and calculate BS and AUC. The
models used for imputation are typically linear regression for continuous Xmis, logistic
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regression for binary Xmis, polytomous regression for unordered categorical Xmis, and
proportional odds model for ordered categorical Xmis, although more complicated
models could be used. After repeating the first step for M times (we use M=5), the
average of the estimates of BS and AUC from the multiple imputed datasets gives
the final single point estimate. When there is more than one covariate with missing
values, a chained equation approach is used to impute the missing values sequentially
[50]. The program mice() in R is used to implement the multiple imputations and
the different models mentioned above can be built with options.
2.2.3 Inverse Probability Weighting
Inverse Probability Weighting (IPW) weights the complete cases in the calculation
of the quantity of interest. The weight (Wi) is the inverse probability of the observa-
tion being complete (Ri = 1), i.e. Wi = 1/Pr(Ri = 1). We use logistic regression to
build the model of either Pr(Ri = 1|Xi, Yi) or Pr(Ri = 1|Xi) conditional on the fully
observed covariates and outcome to get the estimates of the weight. Then
BSIPW =
N∑
i=1
(Yi − pˆi)2RiWi
N∑
i=1
RiWi
(2.9)
C − indexIPW =
N∑
i=1
N∑
j=1
I(βXi > βXj)I(Yi > Yj)RiWiRjWj
N∑
i=1
N∑
j=1
I(Yi > Yj)RiWiRjWj
(2.10)
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For AUC,
TPRIPW (c) =
n1∑
i=1
I(βXi ≥ c)RiWi
n1∑
i=1
RiWi
FPRIPW (c) =
n0∑
j=1
I(βXj ≥ c)RjWj
n0∑
j=1
RjWj
(2.11)
With the TPRIPW and FPRIPW , ROCIPW and AUCIPW can be calculated fol-
lowing (2.3).
2.2.4 Augmented Inverse Probability Weighting
The IPW method only uses the complete cases, and ignores the subjects with
missing data. One way to improve it is to include information from subjects with
missing data, which is called Augmented Inverse Probability Weighting (AIPW). For
ease of notation we describe the method in the situation of only one covariate having
missing values. In the Appendix we describe how to apply it when multiple covariates
have missing values. First we build a model for the covariate with missing values on
all the other covariates, i.e. F (Xmis|Xobs, Y ) or F (Xmis|Xobs), to get the predicted
mean X∗mis, which is E(Xmis|Xobs, Y ) or E(Xmis|Xobs). This is a single imputation
of the mean and is different from multiple imputation which incorporates random
variation. The X∗mis is created for that variable for all subjects and is different from
MI which only imputes missing values. Then applying the external model to the
dataset with X replaced by X∗ = (X∗mis, Xobs) gives pˆi
∗. Combining this model with
a model for the weight, the AIPW estimator of the BS is
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BSAIPW =
1
N
N∑
i=1
(Yi − pˆi)2RiWi + (Yi − pˆi∗)2(1−RiWi), (2.12)
A subject with complete data has Ri = 1, and contributes (Yi−pˆi)2Wi+(Yi−pˆi∗)2(1−
Wi). A subject with missing values has Ri = 0 and contributes (Yi − pˆi∗)2. Because
all the subjects with complete data or missing values are evaluated, the denominator
is N .
For the C-index,
C−indexAIPW =
N∑
i=1
N∑
j=1
I(Yi > Yj)
{
I(βXi > βXj)RiWiRjWj + I(βX
∗
i > βX
∗
j )(1−RiWiRjWj)
}
N∑
i=1
N∑
j=1
I(Yi > Yj)
(2.13)
A pair of cases and controls Xi, Xj that are both complete has Ri = 1, Rj = 1,
and contributes I(βXi > βXj)WiWj + I(βX
∗
i > βX
∗
j )(1−WiWj). Otherwise, a pair
of cases and controls that has missing value i.e Ri = 0 and/or Rj = 0 contributes
I(βX∗i > βX
∗
j ).
For the area under the ROC curve method of calculating the AUC,
TPRAIPW (c) =
1
n1
n1∑
i=1
I(βXi ≥ c)RiWi + I(βX∗i ≥ c)(1−RiWi)
FPRAIPW (c) =
1
n0
n0∑
j=1
I(βXj ≥ c)RjWj + I(βX∗j ≥ c)(1−RjWj)
(2.14)
A subject with complete data has Ri = 1, and contributes I(βXi ≥ c)Wi + I(βX∗i ≥
c)(1 −Wi). A subject with missing value has Ri = 0 and contributes I(βX∗i ≥ c).
With the TPRAIPW and FPRAIPW , ROCAIPW and AUCAIPW can be calculated
following (2.3).
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2.2.5 Consistency of IPW and AIPW estimators
Considering the C-index using the IPW method. Let
Uij(θ, γ1) = θI(Yi > Yj)RiWiRjWj − I(Yi > Yj)I(βXi > βXj)RiWiRjWj,
where Wi depend on weight model with parameters γ1.
Let UN(θ, γ1) = 0.5N
−2
N∑
i=1
N∑
j=1
[
Uij(θ, γ1) +Uji(θ, γ1)
]
, then it is straight forward
to show that C − indexIPW is the solution of UN(θ, γ1) = 0. Let UE = E(UN) =
0.5E
[
Uij(θ, γ1) + Uji(θ, γ1)
]
.
Let γ∗1 be the large sample limit of γˆ1 using the weight model Pr(R = 1|Xobs, Y ; γ1).
When the weight model is correctly specified, i.e. Pr(R = 1|Xobs, Y ; γ∗1) = Pr(R =
1|Xobs, Y ), then E(RiWiRjWj) = 1, and it is clear that UE(θ, γ∗1) = 0. Because
UN(θ, γ1) converges uniformly to UE(θ, γ1), C − indexIPW is a consistent estimator.
The proof for AIPW estimators is similar. Here we mimic the proof in Long et.
al. [29], and first demonstrate double robustness for a slightly different estimator,
which we label C − indexAIPW∗ with
C−indexAIPW∗ =
N∑
i=1
N∑
j=1
I(Yi > Yj)
{
I(βXi > βXj)RiWiRjWj + E[I(βXi > βXj)](1−RiWiRjWj)
}
N∑
i=1
N∑
j=1
I(Yi > Yj)
Let
Vij(θ, γ1, γ2) = θI(Yi > Yj)−I(Yi > Yj)
{
I(βXi > βXj)RiWiRjWj+E[I(βXi > βXj)](1−RiWiRjWj)
}
where Wi depend on weight model (Pr(R = 1|Xobs, Y ; γ1) ) with parameters γ1 and
in E[I(βXi > βXj)] the expectation is with respect to the distribution of the missing
covariates and depend on the model (F (Xmis|Xobs, Y ; γ2)) with parameters γ2.
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Let VN(θ, γ1, γ2) = 0.5N
−2
N∑
i=1
N∑
j=1
[
Vij(θ, γ1, γ2)+Vji(θ, γ1, γ2)
]
, then it is straight-
forward to see that C − indexAIPW∗ is the solution of VN(θ, γ1, γ2) = 0. Let VE =
E(VN) = 0.5E
[
Vij(θ, γ1, γ2) + Vji(θ, γ1, γ2)
]
. It is easy to see that VN(θ, γ1, γ2) con-
verges uniformly to VE(θ, γ1, γ2), thus the solution to VN(θ, γ1, γ2) = 0 converges to
the solution of VE(θ, γ1, γ2) = 0.
Let γ∗1 be the probability limits of γ1 using the weight model Pr(R = 1|Xobs, Y ; γ1).
When the weight model is correctly specified, i.e. Pr(R = 1|Xobs, Y ; γ∗1) = Pr(R =
1|Xobs, Y ), then E(RiWiRjWj) = 1.
Let γ∗2 be the probability limits of γ2 using the model for the missing covariates
F (Xmis|Xobs, Y ; γ2). When the model is correctly specified, i.e., E(Xmis|Xobs, Y ; γ∗2) =
E(Xmis|Xobs, Y ), then E
{
I(Yi > Yj){E[I(βXi > βXj)]− I(βXi > βXj)}
}
= 0.
When either working model is correctly specified, it is clear that VE(θ, γ1, γ2) = 0,
and that the θ that solves VE(θ, γ1, γ2) = 0 is the true AUC. Because VN converges
uniformly to VE, C − indexAIPW∗ is a consistent estimator.
The estimator we describe in section 2.4, C − indexAIPW is an approximation to
C − indexAIPW∗, in which instead of calculating E[I(βXi > βXj)] over the distribu-
tion, we propose to use I(βX∗i > βX
∗
j ).
The proof of consistency is similar for Brier score and is shown in the Appendix.
2.3 Simulation Studies
In this section, we present results of numerical studies to investigate the perfor-
mance of the proposed method under different settings. We consider three covariates
and denote them as X1, X2, X3. We consider situations where the given external
model is based on all of X1, X2 and X3, and situations where it is only based on X1
and X2. The true distribution for the internal data, FI(Y |X), is defined as
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logit(Pr(Y = 1)) = 0.25 + 0.7X1 + 0.6X2 − 0.5X3
The internal data are sampled from above model. X1, X2, X3 are sampled from
N(0, 1) and about 40% of X1 is missing. The covariates can be independent, or
correlated with cor(X1, X3) = −0.5. Four different external models are evaluated
using the ”internal” data; (M1) the true model with X1, X2 and X3; (M2) the best
model based on just X1 and X2; (M3) a poor model based on X1, X2 and X3 with
wrong coefficients; and (M4) an incorrect intercept model.
The simulation is conducted as follows:
(a) For M1, we use the true coefficients, M1 = (0.25, 0.70, 0.60,−0.50). For M2,
we obtain the coefficients for the external model by generating a data set of 100000
observations from the true model, and fitting a logistic model based on X1 and X2.
For independent covariates, M2 = (0.25, 0.67, 0.58, 0). For cor(X1, X3) = −0.5,M2 =
(0.25, 0.91, 0.58, 0). It is noted that with independent covariates, the estimated coef-
ficients are biased toward the null compared to the true model [35]. With correlated
X1, X3 and X3 is omitted, the estimates of the coefficients for X1, X2 are biased in
opposite directions in the reduced model. For M3, we obtain the coefficients by gen-
erating an external dataset with sample size 50. For independent covariates, M3 =
(0.26, 0.66, 0.90, 0.39), and for correlated covariates, M3 = (0.53,−0.40, 0.88,−0.75).
With such small sample size, the estimated coefficients are not close to the true val-
ues. For M4, we set different prevalence’s for the external data and internal data, and
M4 = (1.00, 0.70, 0.60,−0.50).
(b) Based on the distributions FI(X), FI(Y |X), get the true AUC and BS for each
of M1,M2,M3 and M4 using their coefficients and equations 2.4 and 2.5. We label
these as the true target values.
(c) Sample internal data with N = 1000, and evaluate the external models
M1,M2,M3,M4 on the internal data. Use different methods to handle the miss-
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Table 2.1: List of methods for comparison. * indicates methods for which the weight
model is misspecified under MAR(X,Y). † indicates methods for which the imputation
model is misspecified.
True target true value based on internal data distribution
Full data without missing
CC complete cases analysis
IPW1* weight model uses X
IPW2 weight model uses X & Y
MI1† imputation model uses X
MI2 imputation model uses X & Y
AIPW1*† weight model uses X, imputation model uses X
AIPW2† weight model uses X & Y, imputation model uses X
AIPW3* weight model uses X, imputation model uses X & Y
AIPW4 weight model uses X & Y, imputation model uses X & Y
ing covariates in the internal data to estimate AUC and BS, repeat 1000 times to get
the mean and standard deviation, and compare with each other and with the true
target value calculated in (b).
We consider four different missingness mechanisms. For MCAR, the missing of X1
is random with probability 0.4, i.e., Pr(X1 is missing)=0.4. For MAR(X2, X3), the
missing of X1 depends on other covariates X2, X3, Pr(X1 is missing)= expit(−0.5 +
2X2 − 2X3). For MAR(X2, Y ), the missing of X1 depends on both covariate X2 and
outcome Y , Pr(X1 is missing)= expit(−0.5 + 2X2 + Y ). For MNAR, the missing of
X1 depends on the value of X1, Pr(X1 is missing)= expit(−0.5 + 3X1).
As listed in Table 2.1, we compared the validation of external models on full
internal data without missing (Full), on complete cases only (CC), IPW with the
weight model excluding outcome Y (IPW1) or including outcome Y (IPW2), MI with
the imputation model excluding outcome Y (MI1) or including outcome Y (MI2).
When calculating AUC by AIPW, the two methods, which are based on the C-
index and the area under the ROC curve respectively, gave almost identical results in
terms of bias and efficiency, thus we show the results for the C-index using a weight
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model that excludes the outcome Y (AIPW1, AIPW3) or includes the outcome Y
(AIPW2, AIPW4) and using an imputation model that excludes the outcome Y
(AIPW1, AIPW2) or includes the outcome Y (AIPW3, AIPW4). For the IPW and
AIPW methods the weight models are regarded as mis-specified in the MAR(X2, Y )
situation if they don’t include Y , i.e. IPW1, AIPW1 and AIPW3, and all IPW and
AIPW weight models are mis-specified in the MNAR situation.
In this simulation, mice() in R with linear regression using bootstrap is used to
implement MI for the missing continuous covariates. glm() with logistic link was
used to build weight models and lm() was used to calculate the predicted X∗1 in the
AIPW method.
2.3.1 Simulation results
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Figure 2.1: Simulation results of mean and relative SD of AUC for existing model
M1: correct model. Column A denotes mean AUC. Column B denotes
SD relative to full data analysis. The four rows are different missingness
mechanisms.
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Figure 2.2: Simulation results of mean and relative SD of Brier score for existing
model M1: correct model. Column A denotes mean BS. Column B de-
notes SD relative to full data analysis. The four rows are different miss-
ingness mechanisms.
Fig.2.1 and Fig.2.2 show the simulation results of AUC and BS for existing model
M1 with independent covariates under MCAR, MAR(X2, X3), MAR(X2, Y ), and
MNAR(X1). Column A shows the bias of the various methods. As expected the
full data analysis does achieve the true target AUC and BS. However, the complete
case analysis is unbiased only in the MCAR setting. MI with Y (MI2) is unbiased
under MCAR and MAR, but without Y (MI1) the bias is more than 10% for both
AUC and Brier score. All the IPW and AIPW methods are unbiased under MCAR
and MAR(X2, X3), regardless of whether Y is included or not. Under MAR(X2, Y )
when Y is related to the missingness, the only unbiased IPW method (IPW2) is the
one including Y , which indicates the importance of correct specification of the weight
model. For AIPW2 and AIPW4, when the weight model includes Y , the results are
unbiased. Without Y in the weight model, AIPW3 includes Y in the imputing model,
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and the results are unbiased too. However, when both weight model and imputing
model exclude Y , as in AIPW1, the results are biased, especially for AUC. For the
double robustness of AIPW, as least one of the weight model and imputing model
need to be correctly specified. Under MNAR for which the missingness depend on
X1, all the methods are biased.
Column B shows the relative SD of the methods comparing with full data esti-
mation. As expected all values are equal to 1.0 or larger. The variance of IPW is
always the largest, since it only weights the complete cases. The variance of AIPW
is between IPW and MI, and is much smaller than IPW under MAR.
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Figure 2.3: Simulation results of mean and relative SD of AUC for existing model
M2: best model based on just X1, X2. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows are
different missingness mechanisms.
For the model M2 with omitted covariate X3, under all scenarios, the reduced
model M2 has lower AUC and higher Brier score compared with true target values
for model M1. This is to be expected since omitting an important covariate will
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Figure 2.4: Simulation results of mean and relative SD of BS for existing model M2:
best model based on just X1, X2. Column A denotes mean BS. Column
B denotes SD relative to full data analysis. The four rows are different
missingness mechanisms.
generally lead to an inferior model. As shown in Fig.2.3 and Fig.2.4 the full model
results do achieve the target true value for M2, and they represent the best that could
be achieved for M2. The relative performance of the various MI, IPW and AIPW
methods for the handling the missing data compared to the full model results are
quite similar to those shown in Fig.2.1 and Fig.2.2, both for bias and SD.
We also considered using a poor external model M3 with wrong coefficients. The
results are shown in Fig.2.5 and Fig.2.6. Again in comparison with full data analysis,
the MI2, IPW2, AIPW2 and AIPW4 appear to give no bias, except in the MNAR
case. The variability of the MI2 method is the smallest.
For the scenario when external data and internal data have different prevalence,
we consider an existing model with the intercept=1 while the other coefficients are
the same as the true model. The changed intercept in M4 has no influence on the
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Figure 2.5: Simulation results of mean and relative SD of AUC for existing model
M3: poor model based on X1, X2, X3. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows are
different missingness mechanisms.
AUC compared to the true value, since changing the intercept does not change the
discrimination ability. The results are identical to those shown in Fig.2.1. The values
of BS increased compared to situation M1. As shown in Fig.2.7 the relative merits of
the MI, IPW and AIPW methods are similar to the other scenarios.
Overall, for the situations considered in this study, considering both bias and
variability the best methods are MI2 and AIPW4. For correlated covariates, the con-
clusions are the same (see Appendix). With multiple missing covariates, the findings
are broadly similar, but with some differences depending on the missingness pattern.
The simulation results shown in the Appendix, suggest that here MI2 is the best
method.
We note that the model used to impute the missing X in MI2 and create X∗
in AIPW3 and AIPW4 is slightly misspecified. Although it does regress X1 on
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Figure 2.6: Simulation results of mean and relative SD of BS for existing model M3:
poor model based on X1, X2, X3. Column A denotes mean BS. Column
B denotes SD relative to full data analysis. The four rows are different
missingness mechanisms.
X2, X3 and Y , the assumed linear model is not the same as the true distribution
for X1|X2, X3, Y based on how the data was generated from the true model. Fur-
thermore, we use I(βX∗i > βX
∗
j ) to approximate E[I(βXi > βXj)] as in the proof
which is an approximation to a doubly robust method. This, together with the fact
that the AIPW method is an approximation to the doubly robust estimator, may ex-
plain the small bias in the AIPW3 method for the MAR(X2, Y ) case, because in fact
neither the weight model nor the imputing model is correctly specified. However the
misspecified imputing model does not give any noticeable bias for the MI2 method.
2.4 Application
In this section, we applied the proposed methods to evaluate the performance of an
existing model for the risk of recurrence in men with Prostate Cancer. The Cancer
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Figure 2.7: Simulation results of mean and relative SD of BS for existing model M4:
different intercept model. Column A denotes mean BS. Column B denotes
SD relative to full data analysis. The four rows are different missingness
mechanisms.
of the Prostate Risk Assessment (CAPRA) score was published in 2005 and was
based on an initial cohort consisting of >1400 men from the University of California,
San Francisco (UCSF) [9]. A Cox proportional hazards regression model identified
age, pretreatment PSA, Gleason score, percentage of biopsy cores positive for cancer
(PPC), and clinical stage as significant factors associated with biochemical recurrence
(BCR) or secondary treatment. Based on the results of the Cox analysis, points were
assigned as in Table 2.2 to indicate relative risk. For each patient the points would be
added to give an overall CAPRA score. The CAPRA score ranges from 0 to 10, and
every 2-point increase in the score represents an approximate doubling of the risk.
The distribution of the score and the 3 year recurrence-free survival (RFS) rate were
reported in the publication, and are shown in Table 2.3. The AUC can be calculated
from the CAPRA score itself, but the BS requires the predicted probabilities from
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Table 2.3.
Table 2.2: CAPRA score
Variable Level Points
PSA
2.0-6 0
6.1-10 1
10.1-20 2
20.1-30 3
>30 4
Gleason Score
(Primary/Secondary)
1-3/1-3 0
1-3/4-5 1
4-5/1-5 3
T stage
T1/T2 0
T3a 1
Percent positive biopsy
<34% 0
≥ 34% 1
Age
<50 0
≥50 1
Table 2.3: CAPRA score distribution and predicted probabilities derived from the
CAPRA score.
CAPRA Score CAPRA score distribution 3-Yr RFS rate
0-1 27.9% 0.91
2 30.0% 0.89
3 20.6% 0.81
4 10.8% 0.81
5 5.8% 0.69
6 3.0% 0.54
7 or Greater 2.0% 0.24
We sought to estimate the performance of CAPRA using a separate dataset from
the Mayo Clinic. The 1268 patients were treated with surgery between 2008 and 2012
and all patients before 2010 and half patients later were missing PPC values. So in
total 90% of the patients were missing PPC. We considered 3-year RFS as a binary
outcome. We included in our analysis all men who were followed more than 3 years or
developed progression in 3 years. In total, 314 of the 1268 patients had a recurrence
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in 3 years. To validate the prediction of CAPRA score, we compared the CAPRA
score with the outcome to get the AUC, and compared the observed RFS rate for
each CAPRA score as in Table 2.3 with the outcome to get Brier score. Because 90%
patients have missingness in PPC, we used PSA, Gleason Score, T-stage, Age and/or
the outcome to build the weight model for missingness and the imputation model of
PPC in the IPW, AIPW, and MI methods. In the data analysis, mice() in R with
logistic regression is used to implement MI for the missing binary PPC. glm() with
logistic link was used to build weight models and glm() with logistic link was used to
calculate the predicted PPC in AIPW. A bootstrap was used to give 95% confidence
intervals for AUC and BS.
Fig.2.8 shows the analysis results of different methods. The AUC ranged from
0.73 to 0.79, which is similar to other external validation studies of the CAPRA score
for which the c-index for BCR ranged from 0.66 to 0.81 [2]. On the other hand,
the BS values were around 0.16 except for complete case analysis and IPW with the
weight model excluding the outcome variable, which were above 0.4. The complete
case analysis and IPW methods have much wider confidence intervals, while the MI
and AIPW methods have comparable confidence intervals. Little’s test was used and
indicated the missingness is not MCAR (p<0.001) [26], thus complete case analysis
is not an optimal choice. The Odds Ratio of PPC not missing and RFS observed
was 24.1, indicating the missingness was strongly related to the outcome. Thus the
methods in which the weight model includes the outcome should be more reliable.
The imputing model of PPC was built only on the 10% of patients with non-missing
data and was used to impute the other 90% later on, and there could be a large
variation in the model, which could explain the ignorable difference between the two
MI methods with or without outcome. The results for AUC and BS are different,
probably because some CAPRA scores have the same RFS rate.
These results indicate the approaches to handle missing data can result in fairly
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large variation in model performance estimates. Based on the theoretical consider-
ations and the simulation results, we believe the results from MI2 and AIPW4 are
the best to use, and they give very similar estimates for both BS and AUC in this
example.
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Figure 2.8: Varying estimates of mean and 95% confidence interval of AUC and Brier
Scores for prostate cancer example, based on how missing data are han-
dled
2.5 Discussion
We developed new AIPW estimators for predictive model performance metrics in
the setting of missing data. This AIPW approach is shown to have good properties.
We note that an AIPW estimator of the AUC has been previously proposed [29], but
for a different setting with auxiliary variables. Adapting this published approach to
our setting does not lead to equation (2.13), but rather an estimator with weights
in the denominator as in equation (2.10). When the weight model is correctly spec-
ified and with assumed independence of cases and controls, the expectation of the
denominator in equation (2.10) is equivalent to the denominator in equation (2.13) .
When there are missing observations in the internal data, MI and IPW can both
be used to obtain unbiased estimates of BS and AUC if the imputation model or
weight model is correctly specified. When the missingness doesn’t depend on Y , IPW
doesn’t need to include Y in the weight model, while MI does need to include Y in the
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imputation model. When the missingness depends on Y , both IPW and MI need to
include Y . The outcome variable should be included in the imputation model under
all scenarios, because it provides information of the missing covariates. For IPW,
the outcome only need to be included in weight model if the missingness depends on
outcome in order to get the correctly specified weight model. The findings in this
paper clearly support inclusion of the outcome variable Y in models that handle the
missing covariates when evaluating an existing prediction model. Thus overall, even
though in some situations for the IPW and AIPW methods it is not necessary, very
little harm arose from including Y and there is the potential for considerable gain.
Our simulation results suggest that AIPW can be more efficient than IPW, and
also obtain approximate double robustness to mis-specification of the weight model
or the imputing model. Even when both models are mis-specified, resulting estimates
are still less biased than IPW or MI with the wrong weight model or imputing model.
Under all scenarios, MI has the best efficiency comparing to full data analysis. Under
MCAR, AIPW has the same efficiency as MI, while under MAR, AIPW is less efficient
than MI.
One limitation of the IPW and AIPW methods is when there are multiple covari-
ates missing. In this situation there are different possible ways in which the weight
model and the imputation model can be constructed. In he specil cases of blocked
missingness or monotone missingness there are natural ways to construct these mod-
els, and in the simulation study we found similar performance to that of the situation
with a single missing covariate. When the missingness is scattered there are more
choice of how to implement the imputation model, and our simulation results suggest
that AIPW can in fact be a less desirable method than IPW. With multiple missing
covariates the MI methods are still relatively easy to apply by using the chained equa-
tion approach to impute the missing values sequentially, and the simulation results
suggest it is clearly more efficient.
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The problem we consider in this paper is how to estimate the correct AUC and
BS for a different population than the one that was used to develop the prediction
model, when (i) we do not have access to the data that was used to develop the model
and (ii) the dataset we have from the different population has some missing covariate
values. There are a broad set of problems associated with missing covariates and risk
prediction models. One is how to develop a model, for which a much cited reference is
Moons et al [33]. Another set of problems is how to implement an existing risk predic-
tion model for an individual subject when that subject has some missing covariates,
and also will not have the outcome known. Different situations and possibilities exist
here. The model developer may have set up methods to use in the case of missing
data, such as 2k different models, one for each pattern of missingness. The user of
the model may simply try a range of values for the missing variables, to give a range
of predicted probabilities, analogous to sensitivity analysis. If the user of the model
has access to the training data, then the question becomes how to make use of these
data. Alternatively, the user of the model may have access to their own dataset,
with information on both the covariates and outcomes for people in this dataset, and
the individual subject can be considered as coming from the same population as this
dataset, then the question again is how to make use of these data. These challenges
have received limited attention in the statistical literature [32, 20], but have been
expounded upon in a recent publication [18].
Another situation worthy of study, is how to evaluate an existing prediction model,
in a different population, when that different population does not have measured one
of the needed input variables for the prediction model. This would seem to be an
impossible task, unless extra information is available, either in the form of additional
data or knowledge of the joint distribution of the missing variable with the other
variables.
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CHAPTER III
A Utility Approach to Individualized Optimal
Dose Selection Using Biomarkers
3.1 Introduction
The goal of personalized medicine is to give the right treatment to the right patient
at the right dose using all we know about the patient. Available knowledge about
individual patients is increasingly including biomarkers which allow personalizing
treatment decisions. One approach to personalized medicine is to identify the right
patient for a given treatment. For example, in the setting of a single binary outcome
and two potential treatments, Foster et. al [12] proposed a “Virtual Twins” method
involving predicting response probabilities for treatment and control “twins” for each
subject by random forest, and then using regression or classification trees to identify
subgroups of patients with large positive treatment effect estimates. A related but
different approach is to identify the right treatment for a patient, often referred to
as optimal treatment regimes (OTR). A treatment regime is defined as the function
that maps a patient’s covariate vector to one of the treatment choices. One approach
to identify an OTR is a 2-step method that involves building a model for conditional
expectation of the outcome given treatment as the first step, then maximizing the
mean expected reward to get the optimal treatment for each subject. In an alternative
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approach, rather than modeling the marginal outcome, outcome weighted learning
(OWL) methods maximize the reward from following a treatment regime directly,
which is equal to the expected outcome in a subset of patients who actually followed
that regime, inversely weighted by the probability of being assigned to the regime
[55]. Maximizing the reward with respect to the treatment regime is equivalent to
minimizing the expectation for patients who did not follow the regime, and can be
interpreted as minimizing the weighted classification error in a classification problem
[53]. Zhang et. al [54] also proposed the doubly robust augmented inverse probability
weighted estimator (AIPWE) in which an outcome model is combined with a model
for the probability of a treatment which is important when analyzing observational
data. The OWL method has been extended to continuous treatment dose settings
such as optimal dose finding [5].
In many settings, it is not possible to describe a patient’s outcome using a single
variable. For example, in oncology, it is typical to describe patient outcomes in
terms of toxicity and efficacy variables. Several strategies have been proposed for
identifying an optimal treatment or dose based on the trade-off between efficacy and
toxicity. Thall and Cook [46] proposed using efficacy-toxicity trade-off contours that
partition the two-dimensional outcome probability domain such that efficacy-toxicity
pairs on the same contour are equally desirable. Dose could then be selected to
maximize desirability. More commonly, a utility matrix is elicited from clinicians by
assigning numerical utilities to each possible bivariate outcome. The optimal dose is
then defined as the value maximizing the posterior mean utility [15].
Guo and Yuan [15] proposed a Phase I/II trial design incorporating biomarkers
in which the optimal dose for an individual patient is selected to maximize utility. A
joint model of ordinal toxicity and efficacy outcomes is specified and canonical partial
least squares are used to extract a small number of components from the covariate
matrix containing dose, biomarkers, and dose-by-biomarker interactions. Wang et. al
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[49] proposed two approaches to identify a personalized optimal treatment strategy
that maximizes clinical benefit under a constraint on the average risk in the situation
of a binary treatment option and continuous outcomes.
In this paper we propose a utility based method to estimate optimal doses for
individual patients in the setting of binary efficacy and toxicity outcomes. To allow
for potentially large numbers of biomarkers and patient factors we utilize l1-penalty
via LASSO [47]. At the individual level, we find the optimal dose by maximizing
utility functions defined as the probability of efficacy minus the weighted probability
of toxicity, which is equivalent to a utility matrix [40]. The weight term in the
utility equation could be elicited from clinicians to quantify the relative undesirability
of toxicity relative to lack of efficacy. Alternatively it can be viewed as a tuning
parameter selected to achieve a desired overall (at the population level) rate of toxicity.
In the vast majority of oncology treatments and many other disease settings, both
efficacy and toxicity outcomes are monotonically linked to increasing dose. While
“flat” curves are common [38], it is uncommon for increasing dose to lead to decreased
toxicity or efficacy. We note that monotonicity may not hold for outcomes such as
progression free survival which include death as an event, since they are potentially
a consequence of either toxicity or lack of efficacy. When estimating outcomes as a
function of dose only it is often not necessary to impose this constraint. However,
when including many potential dose*biomarker interactions, it is likely that some
patients will be estimated to have decreasing toxicity or efficacy with increasing dose
due to statistical noise. To prevent this and to improve efficiency we propose a method
that constrains the estimated dose-efficacy and dose-toxicity relationships to be non-
decreasing for all patients. We call this constrained LASSO, which can be solved by
decomposition and quadratic programming [16] and alternating direction method of
multipliers (ADMM) [13]. In section 3, we report results of a simulation study and
in section 4 we illustrate the proposed methods using a dataset of patients with lung
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cancer treated with radiation therapy.
3.2 Method
3.2.1 Binary Outcome Setting
We assume the available data, (xi, di, Ei, Ti), i = 1, ..., n, comprises n independent
and identically distributed copies of (x, d, E, T ), where x, a p-dimensional centered
vector of subject-specific features, d ∈ [−1, 1] denotes continuous dose of treatment,
E is the binary efficacy outcome, and T is the binary toxicity outcome. A large
probability of E and small probability of T is preferable.
An individualized dose rule is the map from x to the dose domain: F : Rp →
[−1, 1]. Under F , a patient with covariate x is recommended to dose d = F(x).
For any treatment rule F , the population expected efficacy and toxicity are EF(E)
and EF(T ). Our goal is to estimate an individualized dose rule that maximizes the
population expected efficacy while controlling the overall expected toxicity under
some tolerance level, that is
maxF EF(E) , subject to EF(T ) ≤ τ, (3.1)
where τ is the pre-specified maximal tolerance level of average toxicity.
Define δE(xi, di) =P(E = 1|di, xi)−P(E = 1|di = −1, xi), δT (xi, di) =P(T =
1|di, xi)−P(T = 1|di = −1, xi). δE(xi, di) and δT (xi, di) can be interpreted as the
difference in expected efficacy and toxicity outcomes for a patient if treated at the
lowest dose (di = −1) or some higher dose (di). Let Ex to denote the population
average of the function across the distribution of x. After introducing the Lagrange
multiplier, solving equation (3.1) is equivalent to
maxF Ex[δE{xi,F(xi)} − θδT{xi,F(xi)}], (3.2)
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where θ > 0 is chosen such that Ex[δT{xi,F(xi)}] ≤ τ − Ex[P(T = 1|di = −1, xi)].
The expression in equation (3.2) is a utility function quantifying the trade-off between
efficacy and toxicity. By fitting separate models for E and T using methods such as
logistic regression via maximum likelihood or constrained LASSO as described below,
we can calculate the utility values for individual patients over the range of possible
dose values, and calculate the dose rule that maximizes equation (3.2).
Consider the model logit{P(Y = 1)} = f(x, d, β) = β0 +Wβ between outcome Y ,
i.e. E or T , and covariates including biomarkers x, dose d, and dose-biomarker inter-
actions dx, i.e. W = (x, d, dx). To fit the model we use the generalized LASSO with
l1-penalty on the log-likelihood and no penalty on β0. To enforce a non-decreasing
relationship of efficacy and toxicity with dose, we add constraints on derivatives with
respect to d to be non-negative, i.e., ∂
∂d
f(xi, d, β) ≥ 0 for all xi. We call this method
constrained LASSO (cLASSO), for which the constraint can be written as Cβ ≥ 0,
where C is a n× (2p+ 1) matrix of [0n∗p, 1n∗1,xn∗p]. Then the cLASSO method is to
minimize −logL(β,W, Y )+λ‖β‖1 = −
n∑
i=1
[Yi(β0+Wiβ)−log{1+exp(β0+Wiβ)}]+λ‖β‖1
(3.3)
subject to Cβ ≥ 0.
To solve (3.3) we decompose β into its positive and negative part, β = β+ − β−,
as the relation |β| = β+ + β− handles the l1 penalty term. Let W ∗ = (W,−W ),
and β∗ = (β+T ,−β−T )T . By plugging these into (3.3) and adding the additional
non-negativity constraints on β+ and β−, the constrained LASSO is formulated and
can be solved, for example, by spg() in R, which uses the spectral projected gradient
method for large-scale optimization with simple constraints. That is,
minimize −
n∑
i=1
[Yi(β0 +W
∗
i β
∗)− log{1 + exp(β0 +W ∗i β∗)}] + λ14p+2Tβ∗ (3.4)
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subject to (C,−C)β∗ ≥ 0, β+ ≥ 0, β− ≥ 0.
The derivative of (3.4) with respect to (β0, β
∗) is
−
n∑
i=1
{
Yi(1,W
∗
i )−
exp(β0 +W
∗
i β
∗)
1 + exp(β0 +W ∗i β∗)
(1,W ∗i )
}
+ λ(0, 14p+2
T ) (3.5)
The minimizer to (3.4) always satisfies β+j β
−
j = 0 for j = 1, ..., 2p + 1, as shown in
the Appendix. We use 10-fold cross-validation(CV) to choose λ to minimize the CV
deviance.
For any fixed value of theta, and using the above estimated models of efficacy and
toxicity, we can find the optimal dose for each patient that maximize (3.2), then we
use grid search to find the smallest θ achieving the constraint on toxicity. Specifically
the algorithm is as follows:
1. Set a grid 0 = θ1 < θ2 < ... < θK
2. For each m = 1, ..., K:
(a) set θ = θm
(b) For each subject i = 1, ..., n with covariate xi:
calculate dopti = argmax(δE(xi, d)− θδT (xi, d)), estimate P(E = 1|dopti , xi) and P(T =
1|dopti , xi)
3. Select the smallest θˆ such that Ex[P(T = 1|dopti (θ), xi)] ≤ τ . Then dopti (θˆ) is the
estimated optimal dose for patient i.
For binary outcomes under the logistic link function, both δE(x, d) and δT (x, d) are
functions involving the intercept, main effect of x, as well as dose related covariates
d and dx. Estimation of dopt at given θ for each subject is solved by one-dimensional
optimization using optimize() in R, which uses a combination of golden section
search and successive parabolic interpolation. Because of the non-decreasing dose-
efficacy and dose-toxicity relationship, a larger θ will recommend a smaller dopt, and
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the corresponding population average efficacy and toxicity will be smaller. So the
smallest θ achieving the constraint on average toxicity will achieve the largest average
efficacy. The range and size of the grid can be pre-specified and should include a range
of feasible values. In our simulation and data example, we used a range of 0.01 to 4,
in steps of 0.001. We note that for the determination of dopti , we consider the subject
level E−T trade-off, while for the determination of θ, we look at the population level
E − T trade-off.
3.2.2 Multiple Outcome Setting
In some applications there are multiple toxicity outcomes which must be consid-
ered and balanced against efficacy when selecting treatment dose. Without loss of
generality, we consider two different toxicity outcomes T1, T2 and the goal is to
maxF EF(E) , subject to EF(T1) ≤ τ1,EF(T2) ≤ τ2 (3.6)
where τ1, τ2 are the pre-specified maximal tolerance levels of average toxicity for each
toxicity outcome.
Define δE(xi, di) =P(E = 1|di, xi)−P(E = 1|di = −1, x), δT1(xi, di) =P(T1 =
1|di, xi)−P(T1 = 1|di = −1, xi), δT2(xi, di) =P(T2 = 1|di, xi)−P(T2 = 1|di = −1, xi).
Then equation (3.6) is equivalent to
maxF Ex[δE{xi,F(xi)} − θ1δT1{xi,F(xi)} − θ2δT2{xi,F(xi)}], (3.7)
where θ1 > 0, θ2 > 0 are chosen such that Ex[δT1{xi,F(xi)}] ≤ τ1 −Ex[P(T1 = 1|di =
−1, xi)], and Ex[δT2{xi,F(xi)}] ≤ τ2 − Ex[P(T2 = 1|di = −1, xi)].
We specify parametric logistic models for E, T1, T2 as functions of biomarkers,
dose, and dose-biomarker interactions. Denote the parameter estimates from those
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logistic models as βˆE, βˆT1 , βˆT2 . We propose a random walk and Metropolis algorithm
to select θ1, θ2 to achieve the constraints on toxicity. The algorithm is as follows:
1. Set a chain length, B, fix σ2 > 0 and initialize θ0 = (θ01, θ
0
2) to a starting value
that makes Ex[P(T1 = 1|dopti (θ0), xi)] ≤ τ1,Ex[P(T2 = 1|dopti (θ0), xi)] ≤ τ2.
2. For b = 0, ..., B:
(a) Generate θ˜b+1 ∼ N(θb, σ2I) and θ˜b+1 > 0
(b) For each subject i = 1, ..., n with covariate xi:
compute dopti = argmax{δE(xi, d) − θ˜b+11 δT1(xi, d) − θ˜b+12 δT2(xi, d)}, estimate P(E =
1|dopti (θ˜b+1), xi), P(T1 = 1|dopti (θ˜b+1), xi), and P(T2 = 1|dopti (θ˜b+1), xi)
(c) Compute q = min[1,Ex{P(E = 1|dopti (θ˜b+1), xi)}/Ex{Pr(E = 1|dopti (θb), xi)}]
(d) Generate U ∼ U(0, 1);
if Ex[P(T1 = 1|dopti (θ˜b+1), xi)] ≤ τ1,Ex[P(T2 = 1|dopti (θ˜b+1), xi)] ≤ τ2, and U ≤ q, set
θb+1 = θ˜b+1; otherwise, set θb+1 = θb
3. After generating a chain (θ0, ..., θB), we select the θk that leads to the largest value
of Ex[P(E = 1|dopti (θk), xi)] as the optimal solution, and the dopti (θk) is the optimal
dose for patient i.
In stage 2(b) in the above algorithm, dopt at given θ for each subject is solved by
one-dimensional optimization using optimize() in R. The variance of the proposal
distribution σ2 in stage 2(a) is chosen to make the acceptance proportion between
0.25 and 0.5. When there are multiple constraints we found that the random walk
and Metropolis algorithm is more efficient than using a finite grid search over the
multiple dimensions of θ. In our experience, as long as the chain is long enough, the
maxima of the population average efficacy will be achieved. This can be checked by
running the algorithm in parallel for different initial choices of θ0. It is noted that
there is no guarantee that both toxicity constraints will be met at the boundary.
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3.3 Simulation Studies
In this section, we performed numerical studies to investigate the performance
of the proposed method under different settings. We simulated five i.i.d covariates,
x1, ..., x5 from a standard normal distribution, d from Uniform(-1,1), and then gener-
ated N=200 binary outcomes E and T from the regression models
logit(P(E = 1)) = β0,E +WEβE,
logit(P(T = 1)) = β0,T +WTβT ,
where WE = WT = (x, d, dx). A range of scenarios for β were considered, but we
first describe scenario 0, as given in Table 4.1. For scenario 0 (β0,E, βE) =(0, 1,
0, 0, 0, 0, 1, .4, .4, .4, -.8, 0), and (β0,T , βT ) =(-1.386, -1, 0, 0, 0, 0, 1, -.4, -.4,
-.4, .8, 0). In generating x’s, we also applied the constraints that x must satisfy
1 + 0.4x1 + 0.4x2 + 0.4x3 − 0.8x4 > 0 and 1 − 0.4x1 − 0.4x2 − 0.4x3 + 0.8x4 > 0 to
reflect the non-decreasing dose-efficacy and dose-toxicity curves for all subjects. This
excludes up to 35% of the originally simulated observations.
To illustrate the utility approach to dose selection, we plotted individual level
E-T trade-off for three different subjects in Fig.3.1 and population level E-T trade-off
in Fig.3.2. Different dose-efficacy and dose-toxicity curves among subjects result in
selection of different optimal dose values across θ.
For variable selection, we forced the main effect for dose to be selected by removing
its associated parameter from the penalty term and only consider the selection of
covariates and dose*covariate interactions. The methods we compared are forward
selection (FS), regular LASSO, cLASSO and fixed dosing (FD) in which dose only
logistic models were fit. FS was implemented by step() in R using AIC as criteria.
Regular LASSO was implemented by glmnet() in R with 10-fold CV.
The boxplots in Fig.3.3 shows the average efficacy from the above methods with
the same toxicity constraint, from which we see that cLASSO has higher average
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Figure 3.1: Top: Individual level E-T plot with choice of dose with theoretical βE, βT
for three subjects. The utility curve uses θ = 1. Bottom: Individual level
optimal dose as a function of θ for the same three subjects.
efficacy compared to the other methods, especially fixed-dose. We also calculate the
theoretical improvement from using the true models which would only be known
in a simulation study setting. The improvement, defined as proportion of possible
gain compared to the gain from FD to theory, {EF(E) − EFFD(E)}/{EFTheory(E) −
EFFD(E)}, for FS, regular LASSO, and cLASSO is 0.513, 0.518, 0.589, respectively.
cLASSO has higher efficacy than LASSO for 69.0% of the simulated datasets.
We also considered a null case in which there are no covariates or dose*covariates
interactions with result shown in Fig.3.4, so that the dose effects are the same across
all subjects. The average efficacy with toxicity constrained at 0.2 for theory, FS,
regular LASSO, cLASSO and FD are 0.503, 0.470, 0.490, 0.491, 0.499, respectively.
With no effect of covariates, the dose-only model (FD) is as good as the theory, and
the models with covariates included have slightly worse performance than the dose-
only model. Among the modeling approaches, cLASSO has better performance than
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Figure 3.2: Left: Population level E-T plot with choice of θ with theoretical βE, βT ,
Right: Population level E-T trade-off at different toxicity tolerance levels.
FS.
A few other scenarios were considered: In scenario 1 there are only main effects of
covariate and no dose-covariate interactions, and the main effects of the same x are in
opposite directions in efficacy and toxicity models. In scenario 2, the dose-covariate
interaction effects are the same in efficacy and toxicity models, but the main effects
of covariates are different. In scenario 3 and 4, there are 15 and 45 additional noise
covariates added to increase p from 5 to 20 and 50, to examine the performance with
high dimensional data. In scenario 5 and 6, with the same coefficients as in scenario
0 and 3, the sample size increased to 400. In practice, the covariates may be highly
correlated resulting in multicollinearity. In scenario 7, x’s are not independent and
correlation among x1, x2, x3 are 0.6. We also considered several situations in which
the logistic regression model with linear effects is mis-specified. In scenario 8, the
true effect of covariate x4 is stepwise at 0, i.e., the effect only exits for x4 > 0. But
when fitting models, it is mis-specified as linear. In scenario 9, the true models have
exp(x4) as the covariate, but in the fitted models x4 is used, which is mis-specified. In
scenario 10, an interaction of x2 and x3 is included as main effect in both true models
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Figure 3.3: Simulation results for scenario 0. Boxplot of average efficacy with same
toxicity for 1000 simulation trials. The compared methods are theory with
true coefficients; FS: Forward Selection; LASSO; cLASSO: constrained
LASSO; FD: Fixed Dosing. All methods are constrainted at P(T)=0.20.
Means are 0.599, 0.528, 0.528, 0.539, 0.452, respectively.
for efficacy and toxicity, but in the fitted models this interaction is not included.
Table 3.1 showed the simulation results with the above setting. We also considered
another setting with more covariate main effects and fewer dose-covariate interactions,
and with the non-decreasing constraints, 12% of the simulated observations were
excluded. In scenario 1 and 2, when the dose related coefficients for efficacy and
toxicity models are the same or 0, the main effects of covariates still played a role in the
optimal dose finding with the logistic link, and cLASSO still has better performance
than the other methods. In scenario 3 and 4, with the increased number of noise
covariates, the magnitude of improvement decreased, but the cLASSO still performs
better than the other methods. In scenario 5 and 6, with the larger sample sizes, the
magnitude of improvement increased, and cLASSO outperforms the other methods.
In scenario 7, with correlated covariates where the performance of LASSO is known
to be suboptimal, cLASSO still performs better than LASSO and FS. In scenario
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Figure 3.4: Simulation results for the null scenario. Boxplot of average efficacy with
same toxicity for 1000 simulation trials. The compared methods are the-
ory with true coefficients; FS: Forward Selection; LASSO; cLASSO: con-
strained LASSO; FD: Fixed Dosing. All methods are constrainted at
P(T)=0.20. Means are 0.503, 0.470, 0.490, 0.491, 0.499,, respectively.
8, 9, and 10, when the logistic regression model with linear effects is mis-specified,
all the methods have smaller magnitude of improvement, but cLASSO still performs
better than LASSO and FS, showing the robustness of cLASSO.
In Table B1 in the Supplementary materials we present the results from simula-
tions that considered two toxicity outcomes, T1 and T2. The scenarios were con-
structed using a subset of the previous efficacy and toxicity models as in Table 1 with
toxicity outcome T2 added and constrained at 0.23. The situations considered in-
cluded a variety of biomarker main effects, dose-biomarker interactions, correlations
between the biomarkers and additional noise biomarkers. The results in Table A1
provide similar conclusions regarding the relative merit of cLASSO compared to the
other methods as in the single toxicity outcome case.
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Table 3.1: Simulation results. Summary of average Efficacy improvement compared with fixed dose with P(Toxicity) constrained
to be ≤ 0.2. Results from 1000 simulated trials. Each scenario true logistic models for E and T include main effect for the
biomarkers, dose and biomarker-dose interactions, with coefficients as shown below.
Scenarios
Efficacy and Toxicity model coefficients
FS LASSO cLASSO
Possible cLASSO >
Biomarker Dose Interactions Improvement LASSO
0
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.513 0.518 0.589 0.147 69.0%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
1
E 1 0 0 0 0 1 0 0 0 0 0
0.393 0.659 0.694 0.052 53.3%
T -1 0 0 0 0 1 0 0 0 0 0
2
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.344 0.340 0.375 0.070 56.7%
T -1 0 0 0 0 1 .4 .4 .4 -.8 0
3
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.216 0.332 0.354 0.146 60.4%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
4
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
NA 0.246 0.272 0.146 60.0%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
5
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.692 0.691 0.762 0.148 71.7%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
6
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.433 0.431 0.461 0.148 66.3%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
7
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.561 0.561 0.628 0.147 66.2%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
8
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.378 0.399 0.450 0.200 58.2%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
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Table 3.1 Continued:
Scenarios
Efficacy and Toxicity model coefficients
FS LASSO cLASSO
Possible cLASSO >
Biomarker Dose Interactions Improvement LASSO
9
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.360 0.402 0.481 0.206 64.6%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
10
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.455 0.466 0.551 0.146 69.3%
T -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
0?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.618 0.648 0.694 0.132 62.9%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
1?
E 1 .2 .3 .1 0 1 0 0 0 0 0
0.410 0.590 0.641 0.055 56.4%
T -1 -.2 -.3 -.1 0 1 0 0 0 0 0
2?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.373 0.497 0.647 0.053 77.5%
T -1 -.2 -.3 -.1 0 1 0 .2 -.1 .6 0
3?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.280 0.429 0.460 0.131 62.1%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
4?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
NA 0.307 0.342 0.133 61.7%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
5?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.788 0.802 0.833 0.134 64.0%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
6?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.512 0.613 0.640 0.133 62.0%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
7?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.671 0.716 0.756 0.134 65.0%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
8?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.391 0.435 0.457 0.153 54.8%
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Table 3.1 Continued:
Scenarios
Efficacy and Toxicity model coefficients
FS LASSO cLASSO
Possible cLASSO >
Biomarker Dose Interactions Improvement LASSO
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
9?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.317 0.372 0.435 0.081 65.6%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
10?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.519 0.559 0.624 0.132 68.4%
T -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
a. The intercept for Efficacy models is 0, for Toxicity models is -1.386.
b. Possible Improvement=EFTheory (E)− EFFD (E), the percentage of improvement={EF (E)− EFFD (E)}/{EFTheory (E)− EFFD (E)}.
c. Scenarios 3, 6, 3?, 6? have 15 noise covariates with coefficients 0 added; scenarios 4, 4? have 45 noise covariates with coefficients 0 added.
d. Scenarios 5, 6, 5?, 6? have doubled sample size of 400.
e. Scenario 7, 7? have cor(x1, x2, x3) = 0.6.
f. Scenarios 8, 9, 10, 8?, 9?, 10? have mis-specified models.
In scenario 8, 8?, the true effect of covariate x4 is stepwise at 0, e.g.,logit(P(E = 1)) = x1 + d+ (0.4x1 + 0.4x2 + 0.4x3 − 0.8I(x4 > 0))d.
In scenario 9, 9?, the true models have exp(x4) as the covariate,e.g.,logit(P(E = 1)) = x1 + d+ (0.4x1 + 0.4x2 + 0.4x3 − 0.8exp(x4))d.
In scenario 10, 10?, an interaction of x2 and x3 is included as main effect in both true models for efficacy and toxicity,
e.g.,logit(P(E = 1)) = x1 + x2x3 + d+ (0.4x1 + 0.4x2 + 0.4x3 − 0.8x4)d.
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3.4 Application
In this section, we applied the proposed method to real data collected from patients
with non-small cell lung cancer who received radiation treatment. Patients treated
with stereotactic body radiation therapy or with follow-up less than one year were
excluded from the analysis, leaving 105 patients in the dataset to be analyzed. Of
the 105 patients, 46 had no local, regional or distant progression in two years. Two
toxicity outcomes were considered: grade 3+ heart toxicity and grade 3+ lung toxicity.
In total, 8 patients had grade 3+ heart toxicity, and 11 patients had grade 3+ lung
toxicity that required hospitalization. The clinical features we consider for possible
inclusion in models include sex, age, current smoker, Karnofsky Performance Status
(KPS), concurrent chemotherapy, simple stage, T-stage, N-stage of the cancer, as
shown in Table.3.2. We also include pre-treatment cytokines level such as interferon
γ (IFN-γ), interleukin-1 β (IL-1β), interleukin-2 (IL-2), interleukin-6 (IL-6), tumor
necrosis factor α (TNF-α) as prognostic factors. Patients in this study received
different doses ranging from 45 Gy to 96 Gy, partially due to the preference of different
clinicians as well as the stage of the disease, location of the tumor and the patients
performance status. The dose to the tumor site (efficacy dose) is different from the
dose received by the lung and heart, but we assume the ratio of them is fixed for each
patient. When the optimal efficacy dose is chosen within the observed dose range (45
- 96 Gy), it is multiplied by this known fixed (for each patient) ratio to obtain the
lung and heart dose corresponding to the selected tumor dose. There are 14 patients
with no cytokine data collected, and multiple imputation with all the covariates and
outcomes included is applied to fill in the missing values.
For the given set of doses in the study, the average probability of no progression
in two years (efficacy) is 0.438, the average probability of heart toxicity is 0.076, the
average probability of lung toxicity is 0.105, and average tumor dose across patients
is 71.20 Gy. The goal of this analysis is to estimate an optimal dosing rule that
49
Table 3.2: Descriptive statistics of patients (n=105)
Variable Mean Range
Age (Years) 65.43 39.60 - 85.20
KPS 85.52 60 -100
IFN-γ 113.31 0.52 - 6547.50
IL-1β 10.26 0.04 - 92.61
IL-2 23.50 0.04 - 312.22
IL-6 41.93 0.07 - 730.84
TNF-α 18.48 0.54 - 149.37
Tumor dose (Gy) 71.20 45.66 - 96.08
Lung dose (Gy) 14.47 3.17 - 26.11
Heart dose (Gy) 12.22 0.02 - 46.13
Variable Category Percentage
Gender Female 24
Male 76
Smoking Current 42
Never or former 58
chemotherapy Yes 85
No 15
Simple stage 1 10
2 10
3 79
4 1
T stage 1 18
2 23
3 27
4 32
N stage 0 23
1 12
2 45
3 20
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Table 3.3: Variable selections in each model
Method cLASSO
Model Efficacy Heart toxicity Lung toxicity
Main effect
Dose ? ? ?
Age ?
Sex
Smoking
KPS ? ?
Chemotherapy ?
S stage
T stage ?
N stage ?
IFN-γ — —
IL-1β — —
IL-2 — —
IL-6 — —
TNF-α — — ?
Interactions with dose
Age ? ?
Sex ?
Smoking
KPS
Chemotherapy
S stage
T stage
N stage ?
IFN-γ — —
IL-1β — — ?
IL-2 — —
IL-6 — —
TNF-α — —
Estimated outcomes if these patients were
treated at optimal doses
0.485 0.077 0.108
− represents a covariate which is not considered for inclusion in the model.
? represents a covariate selected by cLASSO for the corresponding model.
Empty cell represent covariates considered for inclusion but not selected by cLASSO.
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maximize the probability of no progression in 2 years, with heart and lung toxicity
level no greater than observed overall toxicity for this population of patients. The
efficacy model for the probability of no progression in two years including as covari-
ates the 8 clinical features with their interactions with tumor dose as well as tumor
dose has in total 17 possible covariates. The heart toxicity model is built similarly,
and the lung toxicity model also includes the 5 most important cytokines and their
interaction with lung dose. Table 3.3 showed the covariates selection by cLASSO in
each model. The random walk method of selecting θ ran for 5000 iterations to ensure
convergence. With the models built by cLASSO, using the selected optimal dose for
each patient gave an expected efficacy of 0.485, an expected heart toxicity at 0.077,
an expected lung toxicity at 0.108, and the average tumor dose across patients was
80.21 Gy. With similar expected lung toxicity and heart toxicity rates, the average
efficacy increased by 0.047 from 0.438 to 0.485, which is a clinically significant im-
provement. Fig 3.5 showed the selected optimal dose for each patient. Some patients
were recommended lower doses comparing to their actual doses received, while more
patients were recommended higher doses. Mean optimal tumor dose is 80.2 Gy, which
is higher than mean actual tumor dose 71.2 Gy.
3.5 Discussion
In this paper, we propose an optimal individualized dose finding rule by maximiz-
ing utility functions for individual patients. This approach maximizes overall efficacy
at a prespecified constraint on overall toxicity. We model the binary efficacy and
toxicity outcomes using logistic regression with dose, biomarkers and dose-biomarker
interactions. To incorporate the larger number of biomarkers and their interaction
with doses, we employed the LASSO with linear constraints on the dose related co-
efficients to constrain the dose effect to be non-negative. Simulation studies show
that this approach can improve efficacy without increasing toxicity relative to fixed
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Figure 3.5: Comparison of selected optimal dose and actual dose received for all the
patients.
dosing. Constraining each patient’s estimated dose-efficacy and dose-toxicity curves
to be non-decreasing improved performance relative to standard LASSO. This utility
method was extended to multiple toxicities.
To force the dose-toxicity or dose-efficacy curve to be non-decreasing with dose,
the constraints for linear combination of dose related coefficients only ensure that the
patients in the current data satisfy this monotonicity criteria, but monotonicity is not
guaranteed for all future patients whose x is not in the observed data. An alternative
approach that would ensure monotonicity with respect to dose for all patients would
be to force all relevant dose and dose-covariate coefficients to be non-negative. But
with the dose-biomarker interactions, it is unnecessary to force all the dose related
coefficients to be non-negative, because some of them could be negative but the linear
combination of them is non-negative for a selected range of dose and covariate values.
Thus, simply constraining all the dose related coefficients to be non-negative is too
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conservative. It is noted that our method is not appropriate in cases where the toxicity
or efficacy endpoint may first increase and then decrease with increasing dose, but is
still applicable when there is an increasing effect followed by a plateau.
While we implemented a constrained version of LASSO, other penalized regression
approaches such as Elastic Net could also be considered [56], or Bayesian methods
using Bayesian LASSO [36], or other Bayesian variable selection methods such as
“spike-and-slab” [22].
Our method constrains the population averaged toxicity level to be below a given
tolerance level. This does not explicitly put any upper bound on the expected toxicity
probability for an individual patient. Our method could be modified by including
an upper bound on the probability of toxicity for each patient. Thus, in addition
to constraints on average toxicity, we also consider adding constraints to individual
toxicity, i.e., adding large penalty for extremely high toxicity, which will make the
utility function more complex. An indirect way of achieving this would be to use a
non-linear function of the probability of toxicity, rather than just the toxicity rate in
equation (3.1).
In this paper we have considered binary outcomes and logistic models that in-
cluded main effect and dose-biomarker interactions. The method could be generalized
to other type of outcomes, such as censored survival times for the efficacy outcome.
An ordinal outcome for toxicity could also be accommodated by requiring a different
tolerance threshold for each level of toxicity. More flexible forms for the effect of dose
and biomarkers could also be considered (e.g., regression splines), and provided the
dose monotonicity constraint can be algebraically formulated, the cLASSO would still
be applicable.
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CHAPTER IV
Utility Based Approach in Individualized Optimal
Dose Selection Using Machine Learning Methods
4.1 Introduction
Precision medicine is an approach for the treatment of a disease that takes into
account individual variability. In many situations, the clinical decision is whether to
give a particular treatment or a standard treatment to the patient, and the statistical
goal is to identify the subgroup of patients likely to derive benefit from the treatment
compared to standard treatment. In other settings, the treatment choice is not binary
and in particular consists of choosing the value of a continuous variable, which we
call dose. The goal in this setting is to find the optimal dose for each patient to
maximize the benefit of treatment. With the development of biomarkers, the goal
can be achieved by evaluating how the biomarkers moderate the treatment effect on
the outcome or outcomes. In statistical terms moderation of the treatment effect can
be formulated as the interaction between the biomarkers and dose in a model.
In this paper we consider the setting where there is an existing dataset from pre-
viously treated patients that contains treatment dose, observed efficacy and toxicity
outcomes and covariates possibly including biomarkers. We further assume there is
heterogeneity in the treatment dose given in this dataset. The statistical goal is to
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analyze the data to learn an individualized dosing rule giving an optimal dose as a
function of patient level covariates.
Supervised learning in the form of regression (for continuous outputs) and classi-
fication (for discrete outputs) is an important constituent of statistics and machine
learning. Widely used parametric models such as linear regression and logistic re-
gression are simple, but can suffer from model mis-specification. Concerns about
mis-specification can be reduced by including extra features, such as interactions and
splines, or there are many nonparametric methods that can be used instead. Because
of their greater flexibility, there is less concern about model mis-specification, but
also increased potential for overfitting. Decision Trees such as Classification And
Regression Trees (CART) and random forest, built upon CART, are easy to under-
stand and interpret and have been used in determining the optimal treatment [12].
Their tree structure handles the interaction well but also increases the potential of
overfitting. Methods based on kernel machines are also flexible and have good perfor-
mance with high-dimensional data. Examples of these are Support Vector Machines
as used in the outcome weighted learning(OWL) [55] method, and Gaussian process
[51]. Modern Bayesian semiparametric and nonparametric models also provide pos-
terior uncertainty quantification which can be used to provide uncertainty estimates
of patient specific treatment decisions. An example of this is using Bayesian Additive
Regression Trees (BART) to provide individual treatment rules (ITR). This approach
provides the uncertainty of the outcome associated with the optimal ITR [28].
In early phase studies in oncology, it is typical to describe the patient outcome
in terms of both toxicity (T) and efficacy (E). The benefit for each patient can be
defined based on combining these two outcomes. By maximizing the potential benefit
for each patient, the individualized optimal treatment or dose will be selected. Several
strategies have been proposed for identifying an optimal treatment or dose based on
the trade-off between efficacy and toxicity. To achieve maximum efficacy with tolera-
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ble toxicity, a utility function can be used as a weighted difference of probabilities of
efficacy and toxicity [23]. More generally, a utility matrix is elicited from clinicians
by assigning numerical utilities to each possible efficacy and toxicity outcome pair,
which allows different preferences for different outcomes and then the utility function,
defined as the expected value of the utility, at different dose levels are compared [19].
Contours characterizing the trade-off between E and T is an alternative and flexible
approach. For this, the set of pairs for the probability of E and the probability of T on
the same contour are equally desirable and the dose that maximizes the desirability
is selected [46].
In oncology and other disease settings, it is frequently reasonable to assume that
increasing dose leads to increased toxicity and efficacy. However, the increase may
not be strictly monotone over the whole range of possible doses. For example, FDA
guidance on cellular and gene therapy products mentions that indicators of potential
benefit appear to plateau above a certain dose [11]. Thus, we will consider constrain-
ing the estimated dose-efficacy and dose-toxicity relationship to be non-decreasing
for all patients. The effect of this should be to reduce the estimation noise, improve
efficiency and hence yield more reliable results.
In previous work we built separate models for E and T and did not explicitly
consider correlation between E and T [23]. In this paper we relax the assumption
of independence and use flexible machine learning methods to build the models for
E and T using dose and biomarkers. In section 3, we propose the use of random
forest and Gaussian process models to build marginal models and link them with a
Gaussian copula. We also build models on joint probabilities and use PAVA isotonic
transformation to give a non-decreasing dose-efficacy and dose-toxicity relationship.
In section 4, we consider alternative uses of the utility function to select an optimal
dose, including the addition of constraints with clinical motivation as well as the
uncertainty of the utility function. A simulation study to compare different model
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building and optimal dose finding methods under several scenarios is summarized in
Section 5. In section 6, we illustrate the proposed methods in a dataset of patients
with non-small lung cancer treated with radiation therapy. We close with discussion
in section 7.
4.2 Utility function and matrix
We assume the available data, Di = (xi, di, Ei, Ti), i = 1, ...N , comprises N inde-
pendent and identically distributed copies of (x, d, E, T ), where x is a Q-dimensional
vector of subject-specific features, d ∈ [−1, 1] denotes continuous dose of treatment,
E is the binary efficacy outcome, and T is the binary toxicity outcome. Denote
pE(d, x) = Pr(E = 1|d, x) and pT (d, x) = Pr(T = 1|d, x) as the marginal probabilities
for the efficacy and toxicity outcomes. One way to combine the efficacy and toxicity
outcomes is through a utility function such as U(p(d, x), θ) = pE(d, x) − θpT (d, x)
with θ > 0. θ can be pre-specified by physicians or calculated as a tuning parameter
to meet a pre-specified level of toxicity in the population [23]. Alternatively, a unique
utility value can also be specified for each possible bi-variate patient outcome (E, T )
in a utility matrix, as shown in Table 4.1. We assign U10 the highest value to the best
possible outcome (efficacy and no toxicity), and U01 the lowest value to the worse
possible outcome (toxicity and no efficacy). U00 and U11 have values in between and
can be larger or smaller or equal to each other. Denote the joint probability of E
and T given d and x as in Table 4.2. We define a utility function as the expectation
of this utility matrix with respect to the joint probability of E and T at dose d and
covariates x. The goal is then to maximize the utility function, or the expectation of
the utility matrix across dose for a fixed x.
The utility function above, U(p(d, x), θ) = pE(d, x)−θpT (d, x), corresponds to one
with (U00, U10, U01, U11) = (0, 1,−θ, 1− θ). More generally, without loss of generality,
we can assign the highest utility as 1 and lowest utility as 0. Then we consider the
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Table 4.1: Utility matrix
E=0 E=1
T=0 U00 U10
T=1 U01 U11
Table 4.2: Table of probabilities
E=0 E=1 Row Sum
T=0 p00 p10 1− pT
T=1 p01 p11 pT
Column Sum 1− pE pE 1
utility matrix with 0 < ω1 < 1, 0 < ω2 < 1 that are pre-specified, as shown in Table
4.3.
Table 4.3: utility matrix with two parameters
E=0 E=1
T=0 ω1 1
T=1 0 ω2
We define the Utility function U¯(p(d, x),ω) as the expectation of the utility matrix
in Table 4.3,
U¯(p(d, x),ω) = ω1p00(d, x) + p10(d, x) + ω2p11(d, x)
= ω1 + (1− ω1)pE(d, x)− ω1pT (d, x) + (ω1 + ω2 − 1)p11(d, x)
(4.1)
When ω1 + ω2 = 1, U¯(p(d, x),ω) = ω1 + (1 − ω1)pE(d, x) − ω1pT (d, x), which
yields equivalent solution to U(p(d, x), θ) = pE(d, x)− θpT (d, x). The gain in utility
when moving from E = 0 to E = 1 is the same for both levels of T (1 − ω1 = ω2).
For this special case the models for E & T can be built separately [23], and no
assumption concerning independence or dependence of E and T is needed. However,
when ω1 + ω2 6= 1, this is not the case and the utility function does depend on the
correlation between efficacy and toxicity.
There are various approaches to modeling the joint distribution of E and T of
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which we consider three: model the marginal distributions for E and T and then
assume independence, or use a copula to link them as the joint distribution, or directly
model the 4 level categorical outcome (E, T ) on d and x.
4.3 Model building
Instead of using parametric models, we will consider using non-parametric ap-
proaches (e.g. random forest) and kernel machines (e.g. Gaussian process) to model
the joint distribution of E and T .
4.3.1 Random forest
First, we use random forest (RF) to build models for E and T separately to obtain
estimates of pˆE(d, x) and pˆT (d, x) for each subject. Here we use Out Of Bag (OOB)
predictions to avoid the overfitting. After obtaining estimated marginal probabilities,
we can assume independence of efficacy and toxicity so that the joint distribution of
(E, T ) is given by the product of the marginals. Alternatively, we can use a copula
to link the marginals as described in the appendix C.1. We can plug the pˆE(d, x)
and pˆT (d, x) for each subject into the copula function and maximize the loglikelihood
across the dataset DN to estimate αˆ, the correlation parameter in the copula. Rborist
by Seligman was used to implement the random forest due to its computational
efficiency [42].
In random forest, the predicted probabilities of E or T may decrease over some
range of dose for some patients. To prevent this, we can apply constraints during the
estimation of the random forest. Specifically, whenever a split on dose is selected, we
require the left node (lower dose) to be associated with lower probabilities of E or T
than the right node (larger dose) [42].
Instead of modeling marginals and linking them to obtain the joint distribution,
we can model the joint probabilities directly. When doing this using methods such
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as random forests, we can’t add monotonicity directly in the model since the desired
monotonicity is in terms of each marginal and not in the four joint probabilities
p00, p10, p01, p11. Thus in this setting we use a post estimation procedure in which
we adjust pˆ00, pˆ10, pˆ01, pˆ11 to obtain pˆ
∗
00, pˆ
∗
10, pˆ
∗
01, pˆ
∗
11 so that the corresponding pE and
pT are monotone in d for all x. Specifically, we use the Pool-Adjacent-Violators
Algorithm (PAVA) isotonic transformation for the marginal distribution, then we
will find a set (pˆ∗00, pˆ
∗
10, pˆ
∗
01, pˆ
∗
11 ) which is close to (pˆ00, pˆ10, pˆ01, pˆ11) and also satisfies
the monotonicity constraint.
For every patient, using the model of categorical outcomes built on the dataset,
we have predictions of (pˆ00, pˆ10, pˆ01, pˆ11) for all the dose levels and thus pˆE and pˆT .
Then we apply PAVA on pˆE and pˆT to get pˆ
∗
E and pˆ
∗
T which is non-decreasing in
dose across the feasible dose range. At each dose, the joint probability pˆ∗11 has a
range of [max(0, pˆ∗E + pˆ
∗
T − 1),min(pˆ∗E, pˆ∗T )]. One way to perform the adjustment
is to minimize |pˆ∗11 − pˆ11| within the allowed range to get pˆ∗11, then pˆ∗10, pˆ∗01, pˆ∗00 can
be calculated sequentially from the known pˆ∗11, pˆ
∗
E, pˆ
∗
T . Another way is to minimize
|pˆ∗11− pˆ11|+|pˆ∗10− pˆ10|+|pˆ∗01− pˆ01|+|pˆ∗00− pˆ00|, which involves all the joint probabilities.
4.3.2 Gaussian process
As a second approach to estimating the marginal distributions, we use a Gaussian
process (GP) approach. Specifically, we model the outcome y as a distorted version
of the process f , where f is a non-linear latent function and is assigned a Gaussian
process prior. For example, a continuous outcome might use a normal distribution
around f , while a binary outcome would use a logistic link or probit link with f .
With the Gaussian prior
f ∼ GP (0,K) = p(f),
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and likelihood
y ∼
n∏
i=1
p(yi|fi),
the Gaussian posterior of p(f |y) is given by
p(f |y) ∼
n∏
i=1
p(yi|fi)N(f |0,K).
where K is a kernel function that represents the distance between subjects in the
covariate space. Multiple kernel functions could be used and we use a Gaussian
kernel with each element in K defined by
k(xi, xj) = η
2exp(−1
2
Q∑
q=1
ρ2q(x
(q)
i − x(q)j )2)
for subjects i and j = 1, ..., N and dimension q = 1, ..., Q. η2 is called the signal vari-
ance or the magnitude, and ρq’s are the characteristic length-scales of the input-space
for each dimension of x. This covariance function implements automatic relevance
determination (ARD) [34], since the length-scale ρq determines how relevant an input
is: if the length-scale is small, the covariance will become almost independent of that
input, effectively removing it from the inference. The ARD can be used in selection
of the dimension x related to the outcome, especially with high dimension data or
sparse data. We assign priors to η, ρq and estimate the posterior distribution of them
from the data.
In our setting, we assume fE ∼ N(0,KE),fT ∼ N(0,KT ) where KE,KT are
different kernel functions for E, T . For each subject, the marginal probabilities are,
Pr(E = 0) = 1− pE = Φ(fE + a),Pr(T = 0) = 1− pT = Φ(fT + b),
here we use a probit link to connect f to the outcome. Because f are centered around
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0, intercepts a, b are used for the unbalanced outcomes. Then the joint probability
can be obtained by the Gaussian copula
p00(d, x) = Φ2[Φ
−1(1− pE),Φ−1(1− pT )|α] = Φ2[fE + a, fT + b|α]
Alternatively, when assume independence of efficacy and toxicity,
p00(d, x) = Φ(fE + a)Φ(fT + b)
The outcome (E, T ) for each subject follows Multinomial(p00, p10, p01, p11) and we
can use a Bayesian approach to estimate (ηE, ρqE, ηT , ρqT , a, b, α) jointly with some
prior distribution. rstan was used to implement the Bayesian analysis of Gaussian
process since it is more efficient and explores complicated posterior distributions bet-
ter compared to rjags [45].
For Gaussian process, there are no methods to ensure monotonicity of predictions
with respect to dose across the entire covariate space. Rather, virtual data points
can be included and the derivative of the Gaussian process (with respect to dose) at
those points can be forced to be non-negative during estimation [39].
4.4 Optimal dose finding
For a subject with covariates x, we can directly calculate the optimal dose when
the true probabilities p(d, x) are known, by maximizing the utility function across
possible dose values. That is
dopt(x) = argmax U¯(p(d, x),ω) (4.2)
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4.4.1 Modified utility functions
In oncology clinical studies, efficacy and toxicity usually increase with dose simul-
taneously, thus high toxicity could be observed with high efficacy. So when maximiz-
ing efficacy, it is usual to have a pre-specified toxicity limit that needs to be satisfied.
We can achieve this by modifying the utility function by increasing the penalty on
higher values of pT (d, x). As an illustration we will modify the utility function such
that if pT (d, x) ≥ 0.3, the weight for toxicity will be tripled, giving a utility function
of
U¯1(p(d, x),ω) = U¯(p(d, x),ω)− 2ω1pT (d, x)I
[
pT (d, x) ≥ 0.3
]
. (4.3)
The individual optimal dose is obtained by maximizing the utility function, and
this optimal dose differs across patients. It is possible that the optimal dose is at
the boundary of the feasible dose region and far from a population fixed dose dfix,
that is the same for everyone. The dfix can be pre-specified as a standard value,
or estimated by fitting a dose-only model without covariates x in it. It might be
clinically desirable to avoid extreme doses. This can be achieved by shrinking the
individual optimal dose towards the population fixed dose, by including a penalty in
the utility function.
U¯2(p(d, x),ω) = U¯(p(d, x),ω)− δ|d− dfix| (4.4)
U¯3(p(d, x),ω) = U¯(p(d, x),ω)− δ(d− dfix)2 (4.5)
where δ is the penalty parameter and dfix is the population fixed dose.
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Figure 4.1: Comparison of utility function contours. (a) U¯ with ω1 = ω2 = 0.5, (b) U¯1 with ω1 = ω2 = 0.5, (c) U¯2 with
ω1 = ω2 = 0.5, δ = 0.1, (d) U¯3 with ω1 = ω2 = 0.5, δ = 0.1, (e) U¯ with ω1 = 0.3, ω2 = 0.5 and independent E and
T, (f) U¯ with ω1 = 0.5, ω2 = 0.3 and independent E and T, (g) U¯ with ω1 = 0.5, ω2 = 0.3 and cor(E,T)=0.8, (h) U¯
with ω1 = 0.5, ω2 = 0.3 and cor(E,T)=-0.8.
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Figure 4.1 shows the trade-off contours over the two-dimensional space with dif-
ferent utility functions. The pairs of (pE, pT ) on each contour are considered to have
the same utility function, as denoted by the solid lines. For a given patient with
covariates x, the pE(d, x) and pE(d, x) among the possible dose range is shown as a
dashed line, and the dose that maximize the utility function is selected, as shown by
the points. When ω1 + ω2 = 1, the utility function is a weighted difference of pE
and pT and results in straight lines. All the other utility functions have curved or
broken lines. For U¯1, the utility function decreases rapidly when pT (d, x) is above the
pre-specified toxicity limit of 0.3. U¯2 and U¯3 have different penalties for dose with
the l2-penalty giving smoother contours. When ω1 + ω2 6= 1, the four plots (e) to
(h) indicate the influence of different ω1, ω2 values and the correlations of E and T.
The lines are curved with p11(d, x), and the joint distribution of E and T plays a role.
These plots shows different choices of optimal dose as the utility function changes.
For (f) to (h), the correlations are 0, 0.8 and -0.8 with the same set of ω1, ω2 and
marginal probabilities for a given patient, the utilities differs a lot, but the optimal
doses are similar.
4.4.2 Use uncertainty of the estimation
The random forest will give the point estimate of the probabilities for the possible
doses, which is pˆ(d, x) and can be plugged into equation (4.2). Then the individual
optimal dose for subject with covariates x is the dose that maximizes the weighted
sum of the utility values using the joint probability estimates. When using Bayesian
estimation, we will get the posterior distribution of the joint probabilities p(d, x) for
the possible doses, and thus the posterior distribution of U¯(p(d, x),ω). The optimal
dose for subject with covariates x is selected as the dose that maximize the posterior
mean of U¯(p(d, x),ω) given the data DN .
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dopt(x) = argmax E(U¯(p(d, x),ω)|DN) (4.6)
To assess the uncertainty of the estimation, we can consider the posterior distri-
bution of the utility function. Then an alternative way to define the optimal dose for
subject with covariates x is as the dose that maximizes the posterior probability that
the utility function is higher than the utility function at some fixed dose which is the
same for everyone.
dopt = argmax P (U¯(p(d, x),ω) > U¯(p(dfix, x),ω)|DN) (4.7)
4.5 Simulation studies
4.5.1 Settings and scenarios
To evaluate the performance of the different methods, we conducted a simulation
study. We consider 11 scenarios by varying the true parameter coefficients, the func-
tional form (e.g. exponential or binary or linear), the number of biomarkers, and the
sample size. For each scenario and each method of analysis and definition of optimal
dose, we fit the models using the training dataset, and evaluated their performance
under the true models which are known only in this simulation setting.
In scenario 1, we generated N=200 observations in a training dataset by simulating
5 i.i.d covariates, x1, ...x5 from a standard normal distribution, d from Uniform(-1,1),
and binary outcomes E and T from the regression model described below with a
copula to link them. The marginal probabilities are defined by models
pE(d, x) = Φ(β0,E + (x, d, dx)βE), pT (d, x) = Φ(β0,T + (x, d, dx)βT )
and α = 0.8 was used in the Gaussian copula to link the two marginal distribu-
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tions. In scenario 1, (β0,E, βE) = (0, 0.49,−1.11, 0.77, 1.51, 0, 1, 0.23, 0.61, 0, 1.69, 0.5),
(β0,T , βT ) = (−1.386, 0, 1.14,−0.33, 0, 0, 1, 0.03, 0.6, 0,−0.42, 1.04). In generating x’s,
we also applied the constraints that x must satisfy 1+0.23x1+0.61x2+1.69x4+0.5x5 >
0 and 1+0.03x1+0.6x2−0.42x4+1.04x5 > 0 to reflect the non-decreasing dose-efficacy
and dose-toxicity curves. This excludes up to 40% of simulated observations.
The other scenarios considered are shown below in Table 4.4 . In all scenarios the
true model coefficients were chosen so that the proportion of observations with E = 1
was about 50− 70% and with T = 1 was about 10− 30%.
Table 4.4: List of scenarios
S0 The true E & T model has only d without covariates x
S1 The true E & T models have x, d, dx
S2 The true E & T models have x, d, no dose-covariate interactions
S3 S1 with x1, x2, x3 correlated with coefficient 0.6
S4 S1 with 15 noise covariates x6, ..., x20 added to the data
S5 S1 with 195 noise covariates x6, ..., x200 added to the data
S6 S1 with sample size = 400
S7 S1 with binary covariates x
S8 The true E & T model has x, d, dx, as well as covariate interactions xx
S9 The true models have exp(x4) as the covariate
S10 The true models have I(x4 > 0) as the covariate
The simulation consist of the following steps iterated 1000 times. 1) Generate a
training dataset of the specified size (N=200 or 400). 2) Fit models for efficacy and
toxicity on the training data. 3) Generate a validation dataset following the same
approach as for the training data. 4) Calculate the estimated optimal dose for each
patient in the validation data using the models estimated from the training data and
a particular method for selecting optimal dose based on the models. Also calculate
the true efficacy and toxicity probabilities for each patient, conditional on the esti-
mated optimal dose, using the true models. 5) Calculate the average and standard
deviation of the estimated optimal dose values, average probability of efficacy, average
probability of toxicity, average value of the true utility function, and average improve-
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ment in utility defined as the fraction of the difference between the expectation of
the utility from the true model and the expectation of the utility from using a fixed
dose. The metrics in step (5) are then averaged over the 1000 simulations to provide
a comparison of the various methods for model building and optimal dose selection
across various scenarios.
We consider several variations of random forest modeling. To allow for correlated
efficacy and toxicity outcomes we take three approaches consisting of using a copula
method to link the marginal models, assuming conditional independence and also
directly modeling the 4 level bi-variate outcome. We also implement a version of
random forest in which the dose effects on efficacy and toxicity are constrained to be
non-negative for all patients and compare these results to unconstrained estimation.
When using random forest to model the 4 level categorical outcome, we also assess
the impact of a post-estimation use of a PAVA algorithm to enforce monotonicity.
For the Gaussian process, we compared different priors for ρq including inverse
gamma prior, Laplace prior and horseshoe prior. They have similar performance with
low dimension of covariates, but the horseshoe prior is better with high dimension as
it allows variable selection. Specifically, ρq ∼ N(0, λ2qτ 2) for q = 1, ..., Q, where λq ∼
cauchy(0, 1), τ ∼ cauchy(0, 1). The global parameter τ pulls all the weights globally
towards zero, while the thick half-Cauchy tails for the local scale λq allow some of the
weights to escape the shrinkage. With large τ , all ρ’s have diffuse priors with very little
shrinkage toward 0, but small τ will shrink all the ρ’s to 0. All the other parameters
have a standard normal distribution as priors. For Gaussian process, we tried both
using copula and assuming independence to link the two marginals. The results were
very similar so we only include those corresponding to the independence assumption.
Although we did investigate imposing monotonicity constraints in Gaussian process
modeling through the use of virtual data points, we did not include these methods in
our simulation because they are time consuming and in limited simulations appeared
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to have little effect on the results. All the methods considered are summarized in
Table 4.5.
The utility matrix plays an important role in optimal dose selection so for each
scenario, we consider three utility matrices. The first places higher utility on the
outcome of both efficacy and toxicity compared to neither efficacy nor toxicity (ω1 =
0.3, ω2 = 0.5). The corresponding utility function is U¯(p(d, x),ω) = 0.3+0.7pE(d, x)−
0.3pT (d, x) − 0.2p11(d, x). The second utility matrix we consider, weights these two
possible outcomes equally (ω1 = ω2 = 0.5). In this setting the correlation plays no
role as it cancels out of the utility function, as U¯(p(d, x),ω) = 0.5 + 0.5pE(d, x) −
0.5pT (d, x). In the third utility matrix we consider, the outcome of no efficacy and no
toxicity is preferred to the outcome of both (ω1 = 0.5, ω2 = 0.3). The utility function
is U¯(p(d, x),ω) = 0.5 + 0.5pE(d, x)− 0.5pT (d, x)− 0.2p11(d, x).
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Table 4.5: List of methods. RF denotes random forest, GP denotes Gaussian process
Model building Optimal dose selection
M1 True model U¯(p(d, x),ω)
M2 RF on marginals with copula U¯(pˆ(d, x),ω)
M3 RF on marginals with independence U¯(pˆ(d, x),ω)
M4 RF on marginals monotone on d with copula U¯(pˆ(d, x),ω)
M5 RF on marginals monotone on d with independence U¯(pˆ(d, x),ω)
M6 RF on marginals monotone on d with copula U¯(pˆ(d, x),ω)− 2ω1pˆT (d, x)I
[
pˆT (d, x) ≥ 0.3
]
M7 RF on marginals monotone on d with copula U¯(pˆ(d, x),ω)− δ(d− dfix)2
M8 RF on categorical outcome U¯(pˆ(d, x),ω)
M9
RF on categorical outcome and PAVA to minimize
|pˆ∗11 − pˆ11|
U¯(pˆ∗(d, x),ω)
M10 GP with independence assumption P (U¯(p(d, x),ω) > U¯(p(dfix, x),ω)|DN)
M11 GP with independence assumption E(U¯(p(d, x),ω)|DN)
M12 Fixed dosing: multinomial logistic regression on dose U¯(pˆ(d),ω)
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4.5.2 Results
Figure 4.2 shows the scatter plot of the estimated optimal doses for one represen-
tative dataset with n = 200 under scenario 1 with ω1 = 0.3, ω2 = 0.5. Under the true
model (M1), the optimal dose would be the minimum or maximum possible value for
many patients. The optimal doses selected by different methods are compared with
the true optimal dose. For the random forest models on the marginals (M2, M3, M4,
M5), the optimal doses for many patients are near the optimal fixed dose, which is
0.63 for this dataset. There is little difference between methods using copula and as-
suming independence (M2 vs M3, M4 vs M5), suggesting that use of the copula does
not have a large impact on the distribution of selected doses. As expected, method
M6 tends to avoid maximum dose and select lower doses than method M4 due to
the individual toxicity limit in the utility function. For method M7, the majority of
the patients have optimal doses around the fixed dose because of the dose penalty
in the utility function. For the random forest with categorical outcomes (M8, M9),
adding PAVA to the predicted probabilities affects the selection of optimal dose. For
method M10 which uses Gaussian process and maximizes the probability of utility
higher than the fixed dose, the majority of the patients have optimal doses around
the fixed dose. For method M11 which uses Gaussian process and maximizes the
posterior mean of the utility function, the distribution of the optimal dose is most
similar to the distribution from the true model.
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Figure 4.2: Distribution of optimal dose of n=200 patients for different methods under scenario 1 with utility 1
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Table 4.6: Comparison of all methods under scenario 1 with utility 1,2,3
True RF monotone RF RF & PAVA GP FD
Method M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
U1
mean dose 0.221 0.206 0.219 0.233 0.245 -0.017 0.379 0.266 0.28 0.337 0.303 0.464
sd dose 0.664 0.479 0.473 0.446 0.439 0.478 0.246 0.522 0.513 0.499 0.63 0
mean E 0.703 0.623 0.625 0.628 0.629 0.532 0.646 0.649 0.651 0.674 0.687 0.658
mean T 0.275 0.294 0.299 0.299 0.304 0.193 0.361 0.322 0.328 0.327 0.325 0.415
mean U¯ 66.1 60.8 60.8 61 60.9 59.2 60 61.1 61 62.3 63.1 58.7
% IP U¯ 1 0.278 0.27 0.3 0.286 0.053 0.17 0.32 0.308 0.484 0.595 0
U2
mean dose 0.017 0.027 0.027 0.03 0.029 -0.117 0.097 -0.009 -0.021 0.033 -0.001 0.142
sd dose 0.667 0.495 0.495 0.469 0.469 0.483 0.255 0.561 0.539 0.476 0.662 0
mean E 0.632 0.571 0.571 0.571 0.57 0.505 0.571 0.568 0.564 0.587 0.6 0.567
mean T 0.191 0.223 0.222 0.218 0.218 0.161 0.253 0.213 0.211 0.222 0.208 0.301
mean U¯ 72.1 67.4 67.4 67.6 67.6 67.2 65.9 67.7 67.6 68.3 69.6 63.3
% IP U¯ 1 0.463 0.463 0.484 0.484 0.433 0.294 0.497 0.486 0.562 0.707 0
U3
mean dose -0.162 -0.095 -0.084 -0.1 -0.086 -0.176 -0.072 -0.178 -0.174 -0.167 -0.215 -0.067
sd dose 0.646 0.478 0.476 0.455 0.451 0.468 0.253 0.532 0.521 0.389 0.601 0
mean E 0.556 0.526 0.529 0.524 0.526 0.489 0.516 0.499 0.499 0.508 0.516 0.5
mean T 0.124 0.179 0.184 0.173 0.178 0.146 0.194 0.155 0.157 0.162 0.136 0.229
mean U¯ 69.6 65.1 65 65.4 65.3 65.5 64.1 65.2 65.2 65.3 67 61.6
% IP U¯ 1 0.432 0.419 0.469 0.452 0.484 0.313 0.445 0.441 0.459 0.668 0
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Table 4.6 shows the summary statistics of the optimal dose, Efficacy, Toxicity and
expectation of utility under scenario 1 with different utility functions. To compare
the various methods on a common scale, we calculate the percent of possible increase
in expected utility relative to fixed dose, denoted by % IP U¯ . Thus by definition the
fixed dose approach has 0 percent improvement and the true models have 100 percent
improvement with other methods generally falling in between these values. When
using utility 1, ω1 < ω2, so on average the optimal dose is higher and as a result,
average efficacy and average toxicity are both higher. Under utility 3, ω1 > ω2, the
average optimal dose is lower, and average Efficacy and average Toxicity are lower.
Under this scenario, within each utility function, use of the true models results in the
highest average expected utility, and the fixed dose results in the lowest average of
expectation of utility. The Gaussian process methods (M10, M11) have the highest
mean utility values with the other methods having generally similar performance
varying somewhat across utility matrices.
In practice, all covariates (e.g. biomarker panel) may have no true association
with the patient outcomes so we also consider a null scenario (S0) in which the E
and T models have only d without covariates x in them. Thus the dose effects are
the same across all patients. As shown in Figure 4.3, the dose-only model has nearly
as high of utility values as are possible using the true model. All other modeling
approaches which consider other covariates, generally have poorer utility values than
fixed dosing in this setting.
The comparison of expectation of utility under all scenarios is shown in Figure
4.3 and figures in the appendix, Fig C1, Fig C2. Table 4.7 shows the comparison of
percentage of expectation of utility improvement under all scenarios with utility 1. In
scenario 2, when there are only dose main effects and no dose-covariate interactions,
the main effects of the covariates still play a role in optimal dose selection, and the
Gaussian process which maximizes the posterior mean of utility function (M11) is
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Figure 4.3: Simulation results for scenario 0, 1, 2, 3 under utility 1. Boxplot of
population average of expectation of Utility for 1,000 simulation trials.
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better than other methods. In scenario 3, when covariates are correlated, the Gaus-
sian process methods (M11, M10) outperform the other methods. In scenario 4 and 5,
with the increased number of noise covariates, the ARD feature of the Gaussian pro-
cess and the horse-shoe priors help in model building and methods M12 and M13 have
better performance than others, especially in scenario 5 when random forest (M2-M9)
shows no improvement of utility function. In scenario 6, with the larger sample size,
the magnitude of the improvement increases, and Gaussian process methods (M10,
M11) still perform better than others. In scenario 7 when the covariates are all bi-
nary, to our surprise, the random forest methods (M2-M9) all have poor performance,
while Gaussian process methods (M10, M11) still improve the utility function rela-
tive to fixed dosing (M12). In scenario 8, 9, 10, when the marginal models have
covariate interactions or are mis-specified, all the methods have smaller magnitude
of improvement, but the Gaussian process methods (M11, M10) still perform better
than random forest methods (M2-M9), showing their robustness. Across all those
scenarios, the copula makes no difference compared to assuming independence (M2
vs M3, M4 vs M5). Including the monotonicity in random forest leads to a small
improvement in the mean utility function (M4 vs M2). However, adding monotonic-
ity in categorical random forest afterwards does not help, as seen by comparing M9
vs M10. As shown in Figure 4.2, the optimal dose distribution of Gaussian process
which maximizes posterior mean of utility function (M11) is most similar to the true
model (M1), and also has the highest percent improvement in utility. Using Gaussian
process modeling and selecting dose to maximize the posterior probability of higher
utility than associated with fixed dosing (M10), tends to put a lot of patients near
the fixed dose, but still improves the mean utility function compared to fixed dose.
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Table 4.7: Comparison of percentage of utility function improvement under all scenarios with utility 1
True RF monotone RF RF & PAVA GP FD
Scenarios M1 M2 M3 M4 M5 M6 M7 M8 M9 M10 M11 M12
S1 1 0.278 0.27 0.3 0.286 0.053 0.17 0.32 0.308 0.484 0.595 0
S2 1 0.155 0.162 0.247 0.251 0.324 0.123 0.163 0.151 0.247 0.471 0
S3 1 0.144 0.142 0.169 0.164 -0.003 0.152 0.175 0.161 0.35 0.464 0
S4 1 0.177 0.172 0.178 0.172 -0.019 0.097 0.22 0.213 0.451 0.536 0
S5 1 0.014 0.014 0.017 0.016 -0.114 0.008 -0.001 -0.004 0.308 0.29 0
S6 1 0.385 0.376 0.417 0.4 0.105 0.255 0.42 0.412 0.55 0.654 0
S7 1 -0.284 -0.28 -0.017 -0.028 -0.685 0.064 -0.405 -0.259 0.171 0.165 0
S8 1 0.215 0.212 0.242 0.235 0.101 0.155 0.223 0.212 0.411 0.525 0
S9 1 0.062 0.057 0.067 0.058 -0.547 0.103 0.185 0.194 0.268 0.437 0
S10 1 0.04 0.038 0.083 0.079 -0.429 0.134 0.102 0.107 0.259 0.384 0
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4.5.3 Parametric vs non-parametric models
In the above simulation, we compare different non-parametric methods and their
performance in optimal dose selection. In this section, we compare some of them with
parametric models such as logistic regression (M13), LASSO (M14) and constrained
LASSO (CLASSO, M15) proposed by Li.et al. All the parametric models are built on
dose d, covariates x, and dose-covariate interactions dx for the marginals and we use
copula to link them. The results are shown in Table 4.8. When the parametric models
are correctly specified, they are more efficient and do better than the non-parametric
models, as shown by S1, S4 and S7.
Furthermore, we evaluated more mis-specified scenarios when the complexity of
the true model increases. The true efficacy and toxicity models can have more in-
teractions such as covariate interactions xx and dose-covariate-covariate interactions
dxx. The dose effect is g(d) where g(.) is a non-linear function. The efficacy model
has log(d+ 1) instead of d, so the efficacy increases faster at lower doses and tends to
level off. Similarly, the toxicity model has exp(d) instead of d, so the toxicity increases
faster at high doses. In the limited mis-specified scenarios with detailed description
in Table C1, the non-parametric models are comparable to and even outperform the
parametric models as shown by S8, MS1-4.
The parametric models assume a finite set of parameters to estimate, the com-
plexity of the model is bounded even if the amount of data is unbounded. On the
contrary, the non-parametric models can be viewed as having an infinite dimension
of parameters, and the amount of information that the parameters can capture about
the data can grow as the amount of data grows, which is more flexible.
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Table 4.8: Comparison of percentage of utility function improvement under selected scenarios with utility 1 for selected non-
parametric and parametric methods
True RF GP FD Parametric
Scenarios M1 M2 M4 M8 M10 M11 M12 M13 M14 M15
S1 1 0.278 0.3 0.32 0.484 0.595 0 0.759 0.804 0.846
S4: 15 noise x added to data 1 0.177 0.178 0.22 0.451 0.536 0 -0.140 0.679 0.705
S7: binary covariates x 1 -0.284 -0.017 -0.405 0.171 0.165 0 0.49 0.663 0.657
S8: The true models have x, xx, d, dx 1 0.215 0.242 0.223 0.411 0.525 0 0.627 0.642 0.689
MS1: The true models have x, xx, d, dx, dxx 1 0.063 0.110 0.078 0.071 0.241 0 0.210 0.253 0.281
MS2: The true models have x, g(d), g(d)x 1 0.302 0.327 0.282 0.227 0.532 0 0.279 0.331 0.417
MS3: The true models have x, g(d), g(d)x, g(d)xx 1 0.198 0.225 0.198 0.095 0.325 0 0.219 0.285 0.303
MS4: The true models have x, xx, g(d), g(d)x, g(d)xx 1 0.084 0.152 0.095 0.086 0.257 0 0.016 0.107 0.114
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4.6 Application
In this section, we applied the proposed methods to a dataset of patients diagnosed
with non-small cell lung cancer and were treated with radiation treatment. Patients
with follow-up less than 1 year were excluded, leaving 109 patients in the dataset to
be analyzed. Our primary measure of efficacy is lack of disease progression (including
local, regional and distant progression). Of the 109 patients, 50 patients were free
from progression at 2 years, and were considered as E = 1. Our binary toxicity
measure is the occurrence of grade 2 or greater lung toxicity (pneumonitis). Of the
109 patients, 32 experienced this toxicity. There were 20 patients who had both
efficacy and toxicity observed. The baseline clinical features we considered were age,
current smoker status, Karnofsky Performance Status(KPS), T stage and N stage of
the cancer, as shown in the Table 4.9. Patients in this study received tumor doses
ranging from 45 to 96 Gy, partially due to the clinical trial on which they were enrolled
and varying preferences of clinicians, as well as patient factors such as cancer stage,
tumor location and performance status. In Radiation Oncology, the dose to the tumor
site (most relevant dose for predicting efficacy) is different from the dose received by
the normal lung tissue (most relevant for predicting lung toxicity). The ratio of these
two dose values can be assumed to be constant for each patient but varies between
patients due to tumor volume and location within the lung. We apply our methods
to estimate the optimal tumor dose and calculate the implied normal lung dose for
each patient using this fixed ratio.
For the utility matrix, we chose ω1 = 0.4 and ω2 = 0.7, considering an outcome
of both efficacy and toxicity (E = 1, T = 1) as more favorable than an outcome of
neither toxicity nor efficacy (E = 0, T = 0). For the random forest on the marginal
distributions, we include tumor dose and clinical features in the efficacy model, and
lung dose and clinical features in the toxicity model. For the random forest on cate-
gorical outcomes and Gaussian process, we include tumor dose and the ratio of lung
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Table 4.9: Descriptive statistics of patients (n=109)
Variable Mean Range
Age (Years) 65.6 39.6 - 85.2
KPS 86 60 -100
Tumor dose (Gy) 71.6 45.7 - 96.1
Lung dose (Gy) 14.6 3.2 - 26.1
Variable Category Percentage
Smoking Current 47
Never or former 53
T stage 1 18
2 23
3 29
4 30
N stage 0 22
1 13
2 44
3 21
dose to tumor dose as well as clinical features. For the fixed dosing method, we build
a multinomial logistic regression model on tumor dose and the ratio of lung dose to
tumor dose.
The dose only model (M12) selects the highest dose as the best fixed dose (for
all the patients), while other methods select individualized optimal dose for each
patient, as shown in Fig 4.4. There is not much difference between the independence
assumption or using the copula to link the two marginals, as shown by M2 vs M3 and
M4 vs M5. Adding the individual level toxicity penalty (M6) lowers the recommended
doses. Methods M7 with dose penalty tend to favor the estimated best fixed dose
(M12) and recommend the highest dose for the majority of the patients. Use of
the PAVA monotonicity algorithm on predictions from the random forest on the 4-
category outcomes has some impact on the selected optimal dose (e.g. see medians
for M8 vs M9). The Gaussian process methods recommend a wide range of doses to
different patients, as shown by M10 and M11.
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Figure 4.4: Boxplot of optimal doses by different methods for the 109 patients
To illustrate how the proposed utility calculations work we plot in Fig 4.5 the
estimated probabilities of efficacy and toxicity and the corresponding utility functions
versus dose for 3 selected patients. In the top row (a) we show the predictions from
random forest models for efficacy and toxicity with copula to link them (M2), and the
bottom plots (b) show the random forest models for efficacy and toxicity constrained
to be monotone in dose and linked with copula (M4). Without forcing monotonicity,
each of these 3 patients have regions of dose where as dose increases, the estimated
probability of efficacy decreases, which is not plausible. Imposing monotonicity results
in believable estimates and also smooths the dose-efficacy curves somewhat. The
bottom panel (b) of the figure shows optimal doses for methods M4, M6, M7 which
all utilize the same random forest models but differ in how they define optimal dose
from these models. For patients 1 and 2, imposing monotonicity on the dose efficacy
curve, results in a larger optimal dose. Patient 3 represents a patient with high
baseline risk of toxicity exceeding what would typically be expected from dose only
toxicity models. Because the probability of toxicity is higher than 0.3 even at the
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lowest dose, method M6 with the individual toxicity penalty recommends the minimal
dose. A higher dose is recommended from methods M4 and M7 however, as efficacy
increases while toxicity plateaus. Plots showing other methods including M8, M9,
M10, M11 on those three patients are included in the Appendix Fig. C3. The
random forest for the categorical outcome results in non-monotone dose-efficacy and
dose-toxicity relationship, and the PAVA which adjust the curves results in a plateau.
The Gaussian process have smoother curves for dose-efficacy and dose-toxicity, with
the limited sample size, the credible interval of the estimates is wide, as shown by the
shadow around the posterior mean of utility.
The random forest method discretizes continuous variables and the curves are not
as smooth as standard regression models, however in contrast to a parametric model,
they can approximate any arbitrary shaped smooth function with sufficient data and
number of splits.
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Figure 4.5: Optimal dose selected by different methods for three patients. Dose-efficacy and dose-toxicity curves are denoted
by solid lines, expectation of utility values by different methods are denoted by dashed lines, optimal dose selected
by different methods are denoted by points.
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4.7 Discussion
In this paper, we propose to use flexible machine learning methods such as ran-
dom forest and Gaussian process to build models for efficacy and toxicity depending
on the dose and biomarkers. Copula is used to model the joint distribution of the
two outcomes and the non-decreasing dose-efficacy and dose-toxicity relationship is
constrained in the model building. A utility matrix with numerical utilities assigned
to all patient outcome pairs allows the improvement in the utility due to a change
in efficacy to depend on the level of toxicity. For each patient, the optimal dose is
chosen to maximize the utility function or the posterior mean of the utility function.
We further adjust the utility function with more constraints to incorporate clinical
requirements, and consider the uncertainty in the estimation of the utility function
by maximizing the posterior probability of utility function improvement.
In practice, the utility matrix can be pre-specified by clinicians, and evaluated
by using simulations. The simulation may motivate the modification of utility values
ω1 and ω2 in discussion with clinicians. Methods to obtain consensus utilities by
summarizing questionnaires from a group of clinicians can also be used, such as the
Delphi method [3]. Patient’s preference and tolerance of the efficacy and toxicity
outcomes can also be considered, which could help to build an individualized utility
matrix. It is also possible to add more penalties to the utility function to take into
consideration the financial cost of the treatment, which could depend on dose.
The expectation of the utility matrix U¯(p(d, x),ω) has been used to select the
optimal dose for each patient. Given the observed data DN , frequentist estimation
of pˆ(d, x) can be plugged into the utility function for optimization. Alternatively,
Bayesian estimation will give the posterior distribution of p(d, x). The posterior mean
of U¯(p(d, x),ω), which is the average of utility function over the posterior distribution,
is used as the common Bayesian approach for optimal dose selection. However, the
posterior mean of the utility function ignores the variance of the posterior distribution,
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which reflects the uncertainty of the estimation. In this paper, we also propose to
maximize the posterior probability that the utility function is higher than the utility
function at a fixed dose. It is possible that the posterior mean of the utility function
increases slightly with dose, but also has a larger variance, so there is not much
improvement of the posterior probability of an improvement in the utility function.
The posterior probability represents how confident we are about the improvement of
the utility function, which can help clinicians in decision making. In the simulations,
it is shown that using the posterior probability can help to avoid assigning extreme
doses to patients, and shrink the individual optimal dose towards the population fixed
dose.
Non-parametric methods such as random forest and Gaussian process provide
flexible ways to model the outcome with all types of covariates. Some other tree
based methods could also considered, such as BART [7] and gradient boosting trees
[6]. Using Bayesian estimation, Gaussian process and BART are smoother and more
accurate in prediction in terms of AUC and RMSE [25] compared to random forest
and gradient boosting. In addition with the posterior distribution, they can provide
uncertainty of the prediction and 95% credible intervals of estimation. The nature of
the tree structure in random forest, BART and gradient boosting trees means these
methods should be well suited to handle the interaction of dose and covariates. On
the other hand, Gaussian process uses a Kernel function to describe the relationship
across dose and covariates and should work better with continuous variables such as
dose. To accommodate the non-decreasing dose-efficacy and dose-toxicity relation-
ship, monotonicity is needed with respect to dose for all the values of x, that is for
all patients, in the model. Monotonicity on a single covariate can be imposed by
using virtual points in the Gaussian process approach [39], or as a splitting criteria
in random forest and gradient boosting trees. But for BART, in current versions
of the method, the monotonicity will be applied on all covariates [8], which is not
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appropriate for this situation.
In general how to choose prior distributions is a big issue in Bayesian estimation.
For the Gaussian process method, especially with a large number of covariates, we
need to select an appropriate prior for ρ, the weight for each covariate in the kernel
function. A Laplace prior, which is a Bayesian version of robust Lasso regression, did
not perform well in our simulation study when we had a large number of covariates
and sparsity. The spike-and-slab prior is appealing as it puts a substantial point-mass
on zero, but can be computationally intensive with a large number of covariates. The
horseshoe prior has been shown to have comparable performance to the spike-and-
slab prior and is more computationally efficient because of its global parameter and
local scales [4]. We adopted the horseshoe prior in our simulations and found it had
good performance, even with a low number of covariates.
Nonparametric machine learning methods are flexible and they only make weak
assumptions about the underlying functional form. But they generally require a large
sample size to estimate the functions and may suffer from overfitting. Thus the sample
size as well as the number of covariates and the expected complexity of the function
should play a role in determining which method is appropriate in any setting. With
smaller sample size, parametric machine learning methods such as neural networks
can be considered as a powerful tool, or classical methods such as logistic regression
could be appropriate.
The outcomes for defining the utility may be more complex than the binary ones
for E and T considered in this paper. Utility values can be assigned to ordinal
categorical efficacy and toxicity outcomes and the 2x2 utility matrix can be expanded.
Survival outcomes can also be broken down into time intervals and these used to assess
the trade-offs between quality and quantity of life, as in quality adjusted survival
analysis [14].
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CHAPTER V
Discussion
The goal in personalized medicine is to select individualized optimal treatment to
improve the health outcome for each patient based on their characteristics such as
biomarkers. In this dissertation, we consider the statistical challenges in personalized
medicine and propose new methods to build and evaluate models for individualized
treatment in oncology. The questions we are trying to answer include what is the
structure of the model and which input feature or biomarker to include in the model.
When the model is built, we need to evaluate how good the model is and whether it
gives good predictions. How these predictions can be used to decide a treatment is
the final step for individualized optimal dose finding.
In Chapter II, we demonstrate how to evaluate an existing model on a dataset
with missing covariates. MI and IPW can be used to get unbiased BS and AUC if
the imputation model or weight model is correctly specified. AIPW can improve the
efficiency of IPW, and is double robust from mis-specification of the weight model or
the imputing model. In the argument whether to include the outcome variable Y in
models that handle the missing covariate, we find out Y should be included in the
multiple imputation even if missingness does not depend on Y . On the other hand, if
IPW or AIPW methods are used and missingness does not depend on Y , then it does
not appear to be necessary to include Y in either the weight model or the missing
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variable model. The approaches to handle missing data can result in fairly large
variation in model performance estimates, as demonstrated by the prostate cancer
data.
For the individualized treatment, we consider the setting with binary efficacy and
toxicity outcomes, and the treatment consists of giving the dose of a therapy, where
the dose can be any continuous value within a pre-specified range. The next two
chapters focus on how to find the optimal dose for each patient using clinical features
and biomarkers.
In Chapter III, we propose the constrained LASSO method to model the bi-
nary efficacy and toxicity outcomes using logistic link with dose, biomarkers and
dose-biomarker interactions. The l1 penalty of LASSO can help to select important
biomarkers from the large number of potential clinical features. The constraint of the
derivative of the model with respect to dose to be non-negative is used to maintain
the non-decreasing dose-efficacy and dose-toxicity relationship. To maximize the rate
of efficacy while limiting the rate of toxicity, we propose an optimal individualized
dose finding rule by maximizing utility functions for individual patients, which is de-
fined as a weighted combination of efficacy and toxicity probabilities. This approach
can improve efficacy without increasing toxicity compared to the one dose for all
approach.
In Chapter IV, we relax the assumption of independence of efficacy and toxicity
in model building and use copula to model their joint distribution. The correlation
of efficacy and toxicity might change the expectation of the utility, but has not much
impact on the individualized optimal dose selection. Instead of parametric models as
in Chapter III, we use flexible machine learning methods, which is becoming a trend
in statistical analysis. The non-parametric approaches such as random forest and
kernel machines such as Gaussian process can avoid model misspecification and be
more robust. Monotonicity features can also be implemented in random forest and
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Gaussian process to constrain the dose effect to be non-decreasing. The comparison of
these methods to parametric models in this study reveals the pros and cons of them.
In the optimal dose selection, we adjust the utility function with more constraints
to meet the clinical requirement. The individual toxicity penalty helps to avoid
unfavorable toxicity outcomes, and the dose penalty helps to avoid extreme doses
assigned to patients. With the Bayesian estimation of Gaussian process, we also
incorporate the uncertainty of estimation in the dose selection, which help to improve
the utility function and also avoid extreme doses.
In Chapter III and IV, the outcomes we consider are binary efficacy and tox-
icity outcomes. In the lung data analysis, no progression in 2 years is treated as
efficacy E = 1. Some patients with short follow-up and no progression observed
were excluded from analysis because of this transformation of survival outcome to
binary outcome. One point of future consideration is to extend the current meth-
ods to survival outcome. Parametric models such as Weibull model, semi-parametric
models such as Cox proportional hazards model and non-parametric models such as
survival random forest can be used to build models for progression conditional on
dose and covariates. Copula can be used to link the survival model to other models
to implement the joint distribution of efficacy and toxicity. To combine efficacy and
toxicity in individualized optimal dose selection, the predicted progression free sur-
vival probability at a pre-specified time point can be plugged into the utility function.
Alternatively, quality-adjusted survival can be used as a measure that captures the
trade-offs between length and quality of life [14].
The current study focus on the dose assignment at the beginning of the study using
the patient’s baseline information. In a lot of medical practice, multiple treatments
will be given sequentially rather than a single treatment. Whether to repeat a treat-
ment that has obtained a favorable response or to modify it if the current response
is unfavorable is a decision that has to be made. The choice of the next treatment is
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often guided by updated data on the patients disease status and covariates, which are
highly related to the previous treatment. Dynamic Treatment Regimes (DTR) have
been proposed in the sequentially multiple assignment randomized trials (SMARTs)
[48]. How to extend the proposed methods to the multiple-stage DTR is worth further
investigation.
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APPENDIX A
Appendices for Chapter II
A.1 Differences between optimizing the likelihood, the AUC
and the Brier Score
Brier score measures the mean squared difference between the predicted proba-
bility and the actual outcome of an event across all subjects. The lower the Brier
score is for a set of predictions, the better the predictions are calibrated. When we
evaluate an existing model such as a logistic model on the internal dataset, the Brier
score will be minimized when the external model is the same as internal model, i.e,
FE(Y |X) = FI(Y |X).
Proof. Assume the FI(Y |X) as expit(αX) and FE(Y |X) as expit(βX).
Brier score
=
∑
Y
∫
x
(Y − pˆ)2FI(Y |X)FI(X)dX
=
∑
Y
∫
X
(Y − 1
1+exp(−βX))
2( 1
1+exp(−αX))
Y ( exp(−αX)
1+exp(−αX))
(1−Y )FI(X)dX
=
∫
X
[
( exp(−βX)
1+exp(−βX))
2 1
1+exp(−αX) + (
1
1+exp(−βX))
2 exp(−αX)
1+exp(−αX)
]
FI(X)dX
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=
∫
X
exp(−αX)+exp(−βX)2
(1+exp(−βX))2(1+exp(−αX))FI(X)dX
If for any X, exp(−αX)+exp(−βX)
2
(1+exp(−βX))2(1+exp(−αX)) is minimized, then the integral over X will
be minimized.
let A = exp(−αX), B = exp(−βX), then the function can be written as
A+B2
(1 +B)2(1 + A)
Take derivative w.r.t B, we get:
2B(1 +B)2(1 + A)− (A+B2)2(1 +B)(1 + A)
(1 +B)4(1 + A)2
=
2(B − A)
(1 +B)3(1 + A)
When B < A, the function will decrease, When B > A, the function will increase.
Thus it will be minimized at B = A, i.e, when FE(Y |X) = FI(Y |X).
AUC, which measures the area under the ROC Curve, indicates how well the
predicted probabilities for the cases are separated from the controls. The question is
under logistic models will the AUC be maximized when the external model is same
as the internal model, i.e. FE(Y |X) = FI(Y |X)? The answer is it depends. The co-
efficients in the logistic regression model are not chosen to maximize the AUC, rather
the coefficients are chosen to maximize the likelihood. In practice, these two sets of
coefficients will frequently, but not always, be quite similar. However, if complete
discrimination is possible, the maximum likelihood logistic regression coefficients will
estimate the coefficients which separate the population [10, 37].
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A.2 Consistency of IPW and AIPW estimators for Brier
score
Considering the Brier score using the IPW method. Let
Ui(θ, γ1) = θRiWi − (Yi − pˆi)2RiWi,
where Wi depend on weight model with parameters γ1.
Let UN(θ, γ1) = N
−1
N∑
i=1
Ui(θ, γ1), and it is straight forward that BSIPW is the
solution of UN(θ, γ1) = 0. Let UE = E(UN) = E(Ui(θ, γ1)).
Let γ∗1 be the probability limits of γ1 using the weight model Pr(R = 1|Xobs, Y ; γ1)
. When the weight model is correctly specified, Pr(R = 1|Xobs, Y ; γ∗1) = Pr(R =
1|Xobs, Y ), then E(RiWi) = 1, and it is clear that UE(θ, γ1) = 0. Because UN(θ, γ1)
converges uniformly to UE(θ, γ1), BSIPW is a consistent estimator.
The proof is similar for AIPW estimator. We first demonstrate consistency for a
slightly modified estimator, which we call BSAIPW∗ with
BSAIPW∗ =
1
N
N∑
i=1
(Yi − pˆi)2RiWi + E[(Yi − pˆi)2](1−RiWi)
Let
Vi(θ, γ1, γ2) = θ −
{
(Yi − pˆi)2RiWi + E[(Yi − pˆi)2](1−RiWi)
}
,
where Wi depend on weight model with parameters γ1 and E[(Yi − pˆi)2] depend on
the model for missing covariates with parameters γ2.
Let VN(θ, γ1, γ2) = N
−1
N∑
i=1
Vi(θ, γ1, γ2), then it is straightforward to see that
BSAIPW∗ is the solution of VN(θ, γ1, γ2) = 0. Let VE = E(VN) = E(Vi(θ, γ1, γ2)). It
is easy to see that VN(θ, γ1, γ2) converges uniformly to VE(θ, γ1, γ2), thus the solution
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to VN(θ, γ1, γ2) = 0 converges to the solution of VE(θ, γ1, γ2) = 0.
Let γ∗1 be the probability limits of γ1 using the weight model Pr(R = 1|Xobs, Y ; γ1)
. When the weight model is correctly specified, Pr(R = 1|Xobs, Y ; γ∗1) = Pr(R =
1|Xobs, Y ), then E(RiWi) = 1.
Let γ∗2 be the probability limits of γ2 using the model for the missing covariates
F (Xmis|Xobs, Y ; γ2). When the model is correctly specified, i.e., F (Xmis|Xobs, Y ; γ∗2) =
F (Xmis|Xobs, Y ), then E{E[(Yi − pˆi)2]− (Yi − pˆi)2} = 0.
When either working model is correctly specified, it is clear that VE(θ, γ1, γ2) = 0,
and that the θ that solves VE(θ, γ1, γ2) = 0 is the true BS. Because VN converges
uniformly to VE, BSAIPW∗ is a consistent estimator.
For the actual estimator BSAIPW described in section 2.4 instead of calculating
E[(Yi − pˆi)2] where the expectation is over the distribution F (Xmis|Xobs, Y ; γ∗2), we
propose to use (Yi − pˆi∗)2 as an approximation.
A.3 Additional simulation results for correlated covariates
A.4 Implementing AIPW and IPW estimators when more
than one variable has missing values
We propose the IPW and AIPW estimates of AUC and BS for single covariate
missing in the main text and extend it here to more than one variable with missing-
ness. We discuss how to build weight models and models for the missing covariates
under different missing patterns.
First, we consider the block missing of covariates. Without loss of generality,
consider the model with outcome Y and covariates X1, X2, X3, and both X2, X3 are
missing in some subjects. Let R2 indicate X2 is observed and R3 indicate X3 is
observed, then Pr(R = 1) = Pr(R2 = 1, R3 = 1). The weight model can be built
by Pr(R = 1|X1, Y ) or Pr(R = 1|X1), using the fully observed covariates with the
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Figure A1: Simulation results of mean and relative SD of AUC for existing model M1:
cor(X1, X3) = −0.5. Column A denotes mean AUC. Column B denotes
SD relative to full data analysis. The four rows are different missingness
mechanisms.
outcome or not. The models to impute X∗2 and X
∗
3 can be built separately, with
F (X2|X1, Y ), F (X3|X1, Y ) or F (X2|X1),F (X3|X1) from the data of subjects with
R = 1, and then obtain the predictions of X∗2 and X
∗
3 for all the subjects.
Next we look at a scattered pattern of missingness in the covariates. Use the
same notation above with X1 fully observed and X2, X3 are missing in some subjects.
The weight model can be built by Pr(R = 1|X1, Y ) which indicate the complete
cases without any missing, but may not capture the missingness for each covariate.
Alternatively we can assume that the missingness of X2 and X3 are independent, then
Pr(R = 1) = Pr(R2 = 1)Pr(R3 = 1). The weight models for R2 and R3 can be built
separately by Pr(R2 = 1|X1, Y ), Pr(R3 = 1|X1, Y ) or Pr(R2 = 1|X1), Pr(R3 = 1|X1),
using the fully observed covariates with the outcome or not. The models to impute
X∗2 and X
∗
3 can be built separately as in block missingness.
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Figure A2: Simulation results of mean and relative SD of BS for existing model M1:
cor(X1, X3) = −0.5. Column A denotes mean BS. Column B denotes
SD relative to full data analysis. The four rows are different missingness
mechanisms.
For the monotone missingness, X1 is fully observed and both X2, X3 are missing
in some subjects. For those with X2 observed, X3 is missing in some subjects too,
with the probability of missing X3 can depend on the value of X2 under the MAR
scenario. Now Pr(R = 1) = Pr(R3 = 1|R2 = 1)Pr(R2 = 1) and we can build the
model for R2 using all the subjects and the model for R3 using the subjects with
X2 observed. The models to impute X
∗
2 and X
∗
3 can be built separately as in block
missing using the fully observed covariate X1 with the outcome or not. Alternatively,
the model to impute X∗2 can be built with F (X2|X1, Y ) or F (X2|X1) from subjects
with R2 = 1 and get the predictions of X
∗
2 for all the subjects. Then the model to
impute X∗3 can be built with F (X3|X1, X2, Y ) or F (X2|X1, X2) from subjects with
R3 = 1 and get the predictions of X
∗
3 using X
∗
2 as the predictor covariate for all the
subjects.
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A.5 Simulation results when more than one variable has miss-
ing values
We consider the same model with true coefficients in M1 and the covariates are
independent. For block missing, similar as the single covariate missing, we consider
the MCAR: block missing of X2, X3 has probability of 0.4; MAR (X1): block missing
of X2, X3 depends on the value of fully observed covariate X1; MAR (X1, Y ): block
missing of X2, X3 depends on the value of X1, Y ; MNAR: block missing of X2, X3
depends on the value of X2, X3. Fig A3 shows the simulation results after 1000
iterations for AUC, and the results are similar to Fig 2.1 for the single covariate
missing situation.
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Figure A3: Simulation results of mean and relative SD of AUC for existing model
with block missing of more covariates. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows are
different missingness mechanisms.
For scattered missingness, we assume the missing of X2 and X3 are condition-
ally independent. For MCAR: missing of X2 has probability of 0.4 and missing of
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X3 has probability of 0.2; MAR (X1): missing of X2 depends on the value of fully
observed covariate X1 and missing of X3 depends on X1 too with a different prob-
ability; MAR (X1, Y ): missing of X2 and X3 depends on the value of X1, Y with
different probabilities; MNAR: missing of X2 depends on the value of X2 and missing
of X3 depends on the value of X3. As shown in Fig A4, under MCAR, MAR(X)
and MAR(X,Y), the IPW and AIPW methods can get unbiased estimates when the
models for Pr(R2 = 1),Pr(R3 = 1) or the model to calculate X
∗
2 , X
∗
3 are correctly
specified. But the variance are much higher in comparison to MI methods, especially
for AIPW under MAR(X,Y).
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Figure A4: Simulation results of mean and relative SD of AUC for existing model
with scatter missing of more covariates. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows are
different missingness mechanisms.
For monotone missing, we assume the subjects with missing in X2 have missing
in X3 and some subjects with X2 observed have missing in X3 too. For MCAR:
missing of X2 has probability of 0.4 and for those with X2 observed, missing of
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X3 has probability of 0.5; MAR (X1): missing of X2 depends on the value of fully
observed covariate X1, and for those with X2 observed, missing of X3 depends on X1
and X2; MAR (X1, Y ): missing of X2 depends on the value of X1 and Y , and for
those with X2 observed, missing of X3 depends on X1, X2 and Y ; MNAR: missing
of X2 depends on the value of X2, and for those with X2 observed, missing of X3
depends on the value of X3. We compared different choices for the models to obtain
X∗3 , either it includes X2 or independent of X2, and we saw no difference of the
simulation results. In further simulations we saw that using X∗2 to predict X
∗
3 does
not help when X2, X3 are correlated. As shown in Fig A5, under MCAR, MAR(X)
and MAR(X,Y), the IPW and AIPW methods can get unbiased estimates when the
weight model of Pr(R2 = 1),Pr(R3 = 1|R2 = 1) or the model to calculate X∗2 , X∗3 are
correctly specified. The AIPW methods are more efficient than IPW methods.
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Figure A5: Simulation results of mean and relative SD of AUC for existing model
with monotone missing of more covariates. Column A denotes mean AUC.
Column B denotes SD relative to full data analysis. The four rows are
different missingness mechanisms.
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In conclusion, the extension of the IPW and AIPW methods to multiple covariates
missing is feasible and have good performance under block missing and monotone
missing.
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APPENDIX B
Appendices for Chapter III
B.1 The minimizer to problem (3.4) always satisfies β+j β
−
j = 0
for j = 1, ..., 2p+ 1
Proof. Proof by contradiction: Consider the minimizer of (3.4) β = β+−β−. Without
loss of generality, assume we have β+1 > 0, β
−
1 > 0. Consider another representation
of the same β = β˜+ − β˜−.
β˜+1 = β
+
1 −min(β+1 , β−1 ), β˜−1 = β−1 −min(β+1 , β−1 )
β˜+j = β
+
j , β˜
−
j = β
−
j for j = 2, ..., 2p+ 1
Obviously, (β˜+, β˜−) satisfies the constraints of problem (3.4), and β˜+1 + β˜
−
1 <
β+1 + β
−
1 , β˜
+
1 − β˜−1 = β+1 − β−1 .
Then the objective function (3.4) can be bounded as
L(β+, β−)
= −∑ni=1 {yi(β0 +Xi(β+ − β−))− log(1 + eβ0+Xi(β+−β−))}+ λ∑2p+1j=1 (β+ + β−)
= −∑ni=1 {yi(β0 +Xi(β˜+ − β˜−))− log(1 + eβ0+Xi(β˜+−β˜−))}+ λ∑2p+1j=1 (β+ + β−)
> −∑ni=1 {yi(β0 +Xi(β˜+ − β˜−))− log(1 + eβ0+Xi(β˜+−β˜−))}+ λ∑2p+1j=1 (β˜+ + β˜−)
= L(β˜+, β˜−).
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This contradicts with the assumption that (β+, β−) is the minimizer of (3.4).
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B.2 Additional simulation results
Table B1: Simulation results for two toxicities. Summary of average Efficacy improvement compared with fixed dose with
P(Toxicity1) constrained to be ≤ 0.2 and P(Toxicity2) constrained to be ≤ 0.23. Results from 1000 simulated trials. Each
scenario true logistic models for E, T1 and T2 include main effect for the biomarkers, dose and biomarker-dose interactions,
with coefficients as shown below.
Scenarios
Efficacy and Toxicity model coefficients
FS LASSO cLASSO
Possible cLASSO >
Biomarker Dose Interactions Improvement LASSO
A0
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.581 0.549 0.606 0.121 66.3%T1 -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A1
E 1 0 0 0 0 1 0 0 0 0 0
0.682 0.781 0.800 0.036 50.2%
T1 -1 0 0 0 0 1 0 0 0 0 0
T2 -1 0 0 0 0 1 0 0 0 0 0
A2
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.639 0.627 0.695 0.114 67.2%T1 -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A3
E 1 0 0 0 0 1 .4 .4 .4 -.8 0
0.454 0.471 0.510 0.121 59.3%T1 -1 0 0 0 0 1 -.4 -.4 -.4 .8 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A0?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.659 0.661 0.705 0.111 62.3%
T1 -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
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Table B1 Continued:
Scenarios
Efficacy and Toxicity model coefficients
FS LASSO cLASSO
Possible cLASSO >
Biomarker Dose Interactions Improvement LASSO
A1?
E 1 .2 .3 .1 0 1 0 0 0 0 0
0.575 0.677 0.700 0.039 50.9%
T1 -1 -.2 -.3 -.1 0 1 0 0 0 0 0
T2 -1 0 0 0 0 1 0 0 0 0 0
A2?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.702 0.667 0.731 0.125 55.1%
T1 -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
A3?
E 1 .2 .3 .1 0 1 0 .2 -.1 .6 0
0.622 0.593 0.658 0.115 60.3 %
T1 -1 -.2 -.3 -.1 0 1 0 -.2 .1 -.6 0
T2 -1 0 0 0 0 1 -.5 0 0 0 .5
a. The intercept for Efficacy models is 0, for Toxicity1 models is -1.386, for Toxicity2 models is -1.2
b. Possible Improvement=EFTheory (E)− EFFD (E), the percentage of improvement={EF (E)− EFFD (E)}/{EFTheory (E)− EFFD (E)}.
c. The random walk method of selecting θ was run for 1000 iterations.
d. Scenario A2, A2? have cor(x1, x2, x3) = 0.6.
e. Scenarios A3, A3? have 15 noise covariates with coefficients 0 added.
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APPENDIX C
Appendices for Chapter IV
C.1 Using copulas to link two marginal distributions
The marginal cumulative distribution function for a binary outcome Y , which
could be E or T , is F (0) = Pr(Y ≤ 0|d, x) = 1− p, F (1) = Pr(Y ≤ 1|d, x) = 1, where
p is the probability of Y = 1 given d and x.
The copula approach makes use of the property that (VE, VT ) = (F (E), F (T ))
have uniformly distributed marginals. The copula is defined as
c(vE, vT ) = Pr(VE ≤ vE, VT ≤ vT ) = Pr(E ≤ F−1(vE), T ≤ F−1(vT ))
So for the joint probability given d and x, Pr(E = 0, T = 0|d, x) = Pr(F (E) ≤
F (0), F (T ) ≤ F (0)) = Pr(F (E) ≤ 1− pE, F (T ) ≤ 1− pT ), then
p00(d, x) = Pr(E ≤ F−1(1− pE), T ≤ F−1(1− pT )) = c(1− pE, 1− pT )
p10(d, x) = 1− pT − c(1− pE, 1− pT )
p01(d, x) = 1− pE − c(1− pE, 1− pT )
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and
p11(d, x) = c(1− pE, 1− pT )− pE − pT + 1.
Then for each subject, the outcome (E, T ) is from the multinomial distribution with
probabilities p00, p10, p01, p11 and the loglikelihood is
l = I(E = 0, T = 0)log(p00) + I(E = 1, T = 0)log(p10) + I(E = 0, T = 1)log(p01)
+I(E = 1, T = 1)log(p11).
Different copula functions can be used. For this paper a Gaussian copula is
adopted
c(vE, vT ) = Φ2[Φ
−1(vE),Φ−1(vT )|α],
where α is the correlation parameter of Φ−1(vE) and Φ−1(vT ) [43]. The marginal
probabilities pE, pT can be specified by parametric models and parameters can be
estimated jointly in the loglikelihood together with α. Two step estimation methods
can also be used [21], where in the first step estimates are obtained for the parameters
from the marginal models and are then held fixed in the second step, which consists
of maximizing the likelihood to estimate the association function parameter. Joe
and Xu (1996) showed that with the 2-step estimate for parameters is consistent and
asymptotically normally distributed.
C.2 Additional results
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Figure C1: Simulation results for scenario 4-7 under utility 1. Boxplot of population
average of expectation of Utility for 1,000 simulation trials.
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Figure C2: Simulation results for scenario 8-10 under utility 1. Boxplot of population
average of expectation of Utility for 1,000 simulation trials.
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Table C1: List of scenarios to compare parametric vs non-parametric models
S1 The true E & T models have x, d, dx
S4 S1 with 15 noise covariates x6, ..., x20 added to the data
S7 S1 with binary covariates x
S8
The true models have x, xx, d, dx
Of the 5 covariates, coefficients are non-zero for 4 x, 1 xx, 4 dx
MS1
The true models have x, xx, d, dx, dxx
Of the 5 covariates, coefficients are non-zero for 1 x, 1 xx, 1 dx, 2 dxx
MS2
The true models have x, g(d), g(d)x
Of the 10 covariates, coefficients are non-zero for 10 x, 1 g(d)x
MS3
The true models have x, g(d), g(d)x, g(d)xx
Of the 5 covariates, coefficients are non-zero for 1 x, 1 g(d)x, 2 g(d)xx
MS4
The true models have x, xx, g(d), g(d)x, g(d)xx
Of the 5 covariates, coefficients are non-zero for 1 x, 1 xx, 1 g(d)x, 2 g(d)xx
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Figure C3: Optimal dose selected by different methods for three patients. Dose-efficacy and dose-toxicity curves are denoted
by solid lines, expectation of utility values by different methods are denoted by dashed lines, optimal dose selected
by different methods are denoted by points.
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